1
|
Li W, Vazvaei-Smith F, Dear G, Boer J, Cuyckens F, Fraier D, Liang Y, Lu D, Mangus H, Moliner P, Pedersen ML, Romeo AA, Spracklin DK, Wagner DS, Winter S, Xu XS. Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group. Clin Pharmacol Ther 2024; 115:939-953. [PMID: 38073140 DOI: 10.1002/cpt.3144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Accepted: 12/05/2023] [Indexed: 03/13/2024]
Abstract
The intent of this perspective is to share the recommendations of the International Consortium for Innovation and Quality in Pharmaceutical Development Metabolite Bioanalysis Working Group on the fit-for-purpose metabolite bioanalysis in support of drug development and registration. This report summarizes the considerations for the trigger, timing, and rigor of bioanalysis in the various assessments to address unique challenges due to metabolites, with respect to efficacy and safety, which may arise during drug development from investigational new drug (IND) enabling studies, and phase I, phase II, and phase III clinical trials to regulatory submission. The recommended approaches ensure that important drug metabolites are identified in a timely manner and properly characterized for efficient drug development.
Collapse
Affiliation(s)
- Wenkui Li
- Pharmacokinetic Sciences, Novartis Biomedical Research, East Hanover, New Jersey, USA
| | - Faye Vazvaei-Smith
- Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc., West Point, Pennsylvania, USA
| | - Gordon Dear
- Drug Metabolism and Pharmacokinetics, GSK, Ware, UK
| | - Jason Boer
- Drug Metabolism and Pharmacokinetics, Incyte Corporation, Wilmington, Delaware, USA
| | - Filip Cuyckens
- Drug Metabolism and Pharmacokinetics, Janssen R & D, Beerse, Belgium
| | - Daniela Fraier
- Pharmaceutical Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Yuexia Liang
- Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc., West Point, Pennsylvania, USA
| | - Ding Lu
- Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals Inc., Boston, Massachusetts, USA
| | - Heidi Mangus
- Drug Metabolism and Pharmacokinetics, Agios Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Patricia Moliner
- Enzymology and Metabolism, Department of Translational Medicine and Early Development, Sanofi, Montpellier, Occitanie, France
| | - Mette Lund Pedersen
- DMPK, Research and Early Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Andrea A Romeo
- Pharmaceutical Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Douglas K Spracklin
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut, USA
| | - David S Wagner
- Drug Metabolism and Disposition, AbbVie, North Chicago, Illinois, USA
| | - Serge Winter
- Pharmacokinetic Sciences, Novartis Biomedical Research, Basel, Switzerland
| | - Xiaohui Sophia Xu
- Clinical Bioanalysis, Translation Medicine, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA
| |
Collapse
|
2
|
Cuyckens F, Hvenegaard MG, Cassidy KC, Spracklin DK, James AD, Pedersen ML, Scarfe G, Wagner DS, Georgi K, Schulz SI, Schieferstein H, Bjornsdottir I, Romeo AA, Da Violante G, Blech S, Moliner P, Young GC. Recommendations on the Use of Multiple Labels in Human Mass Balance Studies. Drug Metab Dispos 2024; 52:153-158. [PMID: 38216306 DOI: 10.1124/dmd.123.001429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 11/17/2023] [Accepted: 11/27/2023] [Indexed: 01/14/2024] Open
Abstract
The administration of radiolabeled drug candidates is considered the gold standard in absorption, distribution, metabolism, and excretion studies for small-molecule drugs since it allows facile and accurate quantification of parent drug, metabolites, and total drug-related material independent of the compound structure. The choice of the position of the radiolabel, typically 14C or 3H, is critical to obtain relevant information. Sometimes, a biotransformation reaction may lead to cleavage of a part of the molecule. As a result, only the radiolabeled portion can be followed, and information on the fate of the nonlabeled metabolite may be lost. Synthesis and administration of two or more radiolabeled versions of the parent drug as a mixture or in separate studies may resolve this issue but comes with additional challenges. In this paper, we address the questions that may be considered to help make the right choice whether to use a single or multiple radiolabel approach and discuss the pros and cons of different multiple-labeling strategies that can be taken as well as alternative methods that allow the nonlabeled part of the molecule to be followed. SIGNIFICANCE STATEMENT: Radiolabeled studies are the gold standard in drug metabolism research, but molecules can undergo cleavage with loss of the label. This often results in discussions around potential use of multiple labels, which seem to be occurring with increased frequency since an increasing proportion of the small-molecule drugs are tending towards larger molecular weights. This review provides insight and decision criteria in considering a multiple-label approach as well as pros and cons of different strategies that can be followed.
Collapse
Affiliation(s)
- Filip Cuyckens
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Mette G Hvenegaard
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Kenneth C Cassidy
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Douglas K Spracklin
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Alexander D James
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Mette L Pedersen
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Graeme Scarfe
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - David S Wagner
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Katrin Georgi
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Simone I Schulz
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Hanno Schieferstein
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Inga Bjornsdottir
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Andrea A Romeo
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Georges Da Violante
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Stefan Blech
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Patricia Moliner
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| | - Graeme C Young
- Janssen R&D, Beerse, Belgium (F.C.); H. Lundbeck A/S, Copenhagen, Denmark (M.G.H.); Eli Lilly and Company, Indianapolis, Indiana (K.C.C.); Pfizer Inc., Groton, Connecticut (D.K.S.); Novartis, Basel, Switzerland (A.D.J.); Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.L.P.); Sosei Heptares, Cambridge, United Kingdom (G.S.); AbbVie, North Chicago, Illinois (D.S.W.); Bayer AG, Wuppertal, Germany (K.G., S.I.S.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.S.); Novo Nordisk, Maaloev, Denmark (I.B.); Roche Pharma Research and Early Development, Basel, Switzerland (A.A.R.); Servier, Gif-sur-Yvette, France (G.Da.V.); Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (S.B.); Sanofi, Montpellier, France (P.M.); and GSK Research & Development Ltd., Stevenage (G.C.Y.)
| |
Collapse
|
3
|
Nicolas O, Moliner P, Soubayrol P, Vitse O, Roy S, Cabanis MJ, Turner T, Klieber S, Muccio S, Arabeyre C, Brun P. Absorption, Metabolism, and Excretion of [ 14C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity. Clin Drug Investig 2023; 43:653-665. [PMID: 37642857 PMCID: PMC10480245 DOI: 10.1007/s40261-023-01296-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/19/2023] [Indexed: 08/31/2023]
Abstract
BACKGROUND AND OBJECTIVE Tolebrutinib is a covalent inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are thought to be major drivers of inflammation in multiple sclerosis. This excretion balance and metabolism study evaluated the metabolite profile of tolebrutinib in healthy male volunteers. METHODS Six healthy volunteers received a 60-mg oral dose of [14C]-tolebrutinib, and metabolite profiling of 14C-labeled metabolites was performed using a combination of liquid chromatography, mass spectrometry, and radioactivity assay methods. RESULTS Tolebrutinib was rapidly and completely absorbed from the gastrointestinal tract, followed by rapid and extensive metabolism. Excretion via feces was the major elimination pathway of the administered radioactivity (78%). Tolebrutinib was highly metabolized, with 19 metabolites identified in human plasma. Phase 1 biotransformations were primarily responsible for the circulating metabolites in plasma. Seven metabolites that achieved exposure in plasma similar to or higher than the parent compound were characterized biochemically for inhibition of Bruton's tyrosine kinase activity. Metabolite M8 exceeded the exposure threshold of 10% (18%) of the total radioactivity but had little if any pharmacological activity. Metabolite M2 (4% of circulating radioactivity) retained the ability to irreversibly and potently inhibit Bruton's tyrosine kinase in vitro, similar to the parent compound. Tolebrutinib and metabolite M2 had short (3.5-h) half-lives but durable pharmacodynamic effects as expected for an irreversible antagonist. CONCLUSIONS Tolebrutinib was extensively metabolized to multiple metabolites. The hydroxylated metabolite M2 demonstrated similar inhibitory potency toward Bruton's tyrosine kinase as the parent compound. Both tolebrutinib and metabolite M2 likely contributed to pharmacological activity in vivo.
Collapse
Affiliation(s)
- Olivier Nicolas
- Department of Translational Medicine and Early Development, Sanofi, 371 Rue Professeur Blayac, 34184, Montpellier, France.
| | - Patricia Moliner
- Department of Translational Medicine and Early Development, Sanofi, 371 Rue Professeur Blayac, 34184, Montpellier, France
| | - Patrick Soubayrol
- Department of Translational Medicine and Early Development, Sanofi, 371 Rue Professeur Blayac, 34184, Montpellier, France
| | - Olivier Vitse
- Department of Translational Medicine and Early Development, Sanofi, 371 Rue Professeur Blayac, 34184, Montpellier, France
| | - Sebastien Roy
- Department of Integrated Drug Discovery/Isotope Chemistry, Sanofi, Paris, France
| | - Marie-José Cabanis
- Department of Translational Medicine and Early Development, Sanofi, 371 Rue Professeur Blayac, 34184, Montpellier, France
| | - Tim Turner
- MS Neurology Development, Sanofi, Cambridge, MA, USA
| | - Sylvie Klieber
- Department of Translational Medicine and Early Development, Sanofi, 371 Rue Professeur Blayac, 34184, Montpellier, France
| | - Stephane Muccio
- Department of Translational Medicine and Early Development, Sanofi, 371 Rue Professeur Blayac, 34184, Montpellier, France
| | - Catherine Arabeyre
- Department of Translational Medicine and Early Development, Sanofi, 371 Rue Professeur Blayac, 34184, Montpellier, France
| | - Priscilla Brun
- Department of Translational Medicine and Early Development, Sanofi, 371 Rue Professeur Blayac, 34184, Montpellier, France
| |
Collapse
|
4
|
Young GC, Spracklin DK, James AD, Hvenegaard MG, Scarfe G, Wagner DS, Georgi K, Schieferstein H, Bjornsdottir I, van Groen B, Romeo AA, Cassidy KC, Da-Violante G, Bister B, Blech S, Lyer R, Schulz SI, Cuyckens F, Moliner P. Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White Paper. Clin Pharmacol Ther 2023; 113:775-781. [PMID: 35733280 DOI: 10.1002/cpt.2691] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Accepted: 06/15/2022] [Indexed: 11/10/2022]
Abstract
The human absorption, distribution, metabolism, and excretion (hADME) study is the cornerstone of the clinical pharmacology package for small molecule drugs, providing comprehensive information on the rates and routes of disposition and elimination of drug-related material in humans through the use of 14 C-labeled drug. Significant changes have already been made in the design of the hADME study for many companies, but opportunity exists to continue to re-think both the design and timing of the hADME study in light of the potential offered by newer technologies, that enable flexibility in particular to reducing the magnitude of the radioactive dose used. This paper provides considerations on the variety of current strategies that exist across a number of pharmaceutical companies and on some of the ongoing debates around a potential move to the so called "human first/human only" approach, already adopted by at least one company. The paper also provides a framework for continuing the discussion in the application of further shifts in the paradigm.
Collapse
Affiliation(s)
- Graeme C Young
- GlaxoSmithKline Research & Development Ltd., David Jack Centre, Ware, UK
| | | | | | | | - Graeme Scarfe
- AstraZeneca, Cambridge Biomedical Campus, Cambridge, UK
| | | | - Katrin Georgi
- The Healthcare Business of Merck KGaA, Darmstadt, Germany
| | | | | | | | - Andrea A Romeo
- Roche Pharma Research and Early Development, Basel, Switzerland
| | | | | | - Bojan Bister
- Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
| | - Stefan Blech
- Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
| | | | | | | | | |
Collapse
|
5
|
Yun Viladomat S, Enjuanes C, Calero-Molina E, Hidalgo E, Jose-Bazan N, Ruiz M, Jimenez-Marrero S, Garay A, Alcoberro L, Ras M, Ramos R, Pons-Riverola A, Moliner P, Comin-Colet J. Usefulness of telemedicine-based heart failure monitoring according to “eHealth literacy” domains: insights from the iCOR randomised controlled trial. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
The potential positive effect of electronic health (eHealth)-based heart failure (HF) monitoring remains uncertain, largely due to the heterogeneity of the studies published to date. A subgroup of patients in which its key role is particularly uncertain is in the “low literacy” or “computer or digital illiterate” patients mainly due to telemedicine (TM)-based strategies have been often discouraged on the basis of a foreseeable limited benefit in them.
Purpose
The aim of this study was to determine the effectiveness of a TM-based managed care solution across literacy levels and information and communications technology (ICT) skills.
Methods
We performed a sub-analysis on the basis of two literacy domains (traditional and computer literacy) encompassed in the definition of “eHealth literacy” to the HF-patients included in the “insuficiència Cardíaca Optimitzaciό Remota” (iCOR) randomised study comparing TM vs. usual care (UC) in HF-patients. The primary study endpoint was the incidence of a non-fatal HF event after 6 months of inclusion. The event rates of primary (the occurrence of non-fatal HF event) and secondary (all-cause hospitalization, all cause death and the composite endpoint combining of allcause death or non-fatal HF events) study endpoints were calculated for each literacy domains and its combination. Cox proportional-hazards regression models were used to evaluate the effect of “eHealth literacy” dimensions, treatment group and the interaction term “eHealth literacy” domains by treatment group on study endpoints, and p-value was used to compare the different curves.
Results
178 patients were analysed (81 TM vs 90 UC). As far as the “traditional literacy” analyses, 65% of patients had only elementary education and the 6% had no literacy qualifications, defining the low-educated subgroup as “lower literacy” (126 patients, 71%). All the other patients were classified in the “middle or higher literacy” (52 patients, 29%) subgroup. Moreover, concerning new technological management, 128 patients (72%) referred presenting moderate to high difficulties in its handling, constituting the “lower ICT skills” subgroup. The remaining 28% (50 patients) were allocated into the “middle or higher ICT skills” subgroup due to their minor handicap in their ICT use.
The beneficial effect of TM compared to UC strategy was consistent across all literacy domains (pvalue for interaction 0.207 and 0.117 respectively). The risk of experiencing a primary event was significantly lower in patients that underwent allocation to the TM arm compared to UC in both clustered in the “lower literacy” (p-value=0.001) (Picture 1) and those allocated to the “lower ICT skills” (p-value=0.001) (Picture 2) subgroup.
Conclusions
Non-invasive eHealth-based HF monitoring tools are effective compared to UC in preventing HF events in the early post-discharge period, regardless of two “eHealth literacy” domains (“traditional and computer literacy”).
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Yun Viladomat
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - C Enjuanes
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - E Calero-Molina
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - E Hidalgo
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - N Jose-Bazan
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - M Ruiz
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - S Jimenez-Marrero
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - A Garay
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - L Alcoberro
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - M Ras
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - R Ramos
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - A Pons-Riverola
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - P Moliner
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| | - J Comin-Colet
- Bellvitge University Hospital, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), , Hospitalet De Llobregat , Spain
| |
Collapse
|
6
|
Jose-Bazan N, Jimenez-Marrero S, Calero-Molina E, Hidalgo-Quiros E, Enjuanes-Grau C, Ruiz-Munoz M, Ramos-Polo R, Ras M, Yun-Viladomat S, Alcoberro L, Garay A, Moliner P, Calvo E, Garcimartin P, Comin-Colet J. In heart failure, self-care behavior is an independent determinant of health-related quality of life, regardless of the severity of this patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Poor self-care behaviour is associated with a higher risk of readmission and mortality in patients with heart failure (HF). The interplay between self-care and patient-reported outcomes such as health-related quality of life (QoL) has not been fully established.
Purpose
To describe the association between self-care and QoL in real-world cohort of HF patients.
Methods
We conducted an observational, prospective, cohort study of 1120 consecutive patients with chronic HF. We used the modified European Heart Failure Self-care Behaviour Scale 9-item version (EHFSCBS-9) to measure self-care. Scores were inverted and standardized (higher scores indicate better selfcare). To assess QoL, we used the Minnesota Living with Heart Failure Questionnaire (MLHFQ) (higher scores indicate worse QoL). Written informed consent, complete clinical and psychosocial information of patients were obtained at baseline. To determine the impact of global self-care and its dimensions (autonomy-based adherence, consulting behaviour and provider-based adherence), multivariate linear regressions models (backwards stepwise methods) to predict
QoL were constructed. The multivariate parametric and non-parametric associations between EHFSCBS-9 scoresand the β estimated risk of impairment of QoL (defined as MLHFQ scores ≥ median values) were explored using General Additive Models (GAM). All models were adjusted by age, sex and prognostic factors such as LVEF, NYHA, NT-proBNP levels and recent hospitalization among other well-known determinants of HF severity.
Results
A total of 484 patients (43%) were women, mean age was 72±11 years, and mean LVEF was 45±17%. Mean MLHFQ scores were 45±24. Mean EHFSCBS-9 scores were 69±28. There was a significant inverse correlation between EHFScBS-9 and MLHFQ scores (r=−0.158; p-value<0.0001). As shown in Table 1, self-care behaviour and its 3 domains were independent predictors of QoL in 7 out of the 16 associations explored. These models confirmed a weak linear relationship between EHFSCBS-9 scores and MLHFQ scores particularly between global selfcare and consulting behaviour dimension with global, emotional and social dimensions of QoL. Interestingly, when QoL was dichotomized as impaired/preserved QoL, GAM showed a significant non-parametric “U-shape” relationship (p-value<0.05) between EHFScBS-9 scores and the risk of impairment in QoL (Figure 1).
Conclusions
We have shown that self-care behaviour is an independent predictor of health related QoL in HF regardless the level of disease severity. Global self-care and consulting behaviour were particularly and significantly associated with global QoL and emotional and social dimensions of QoL. Interestingly the relationship between self-care scores and the risk of impaired global QoL was non-linear showing a “U-shape” association pointing out that patients with extreme levels of self-care were more likely to experience impairments in QoL.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- N Jose-Bazan
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - S Jimenez-Marrero
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - E Calero-Molina
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - E Hidalgo-Quiros
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - C Enjuanes-Grau
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - M Ruiz-Munoz
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - R Ramos-Polo
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - M Ras
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - S Yun-Viladomat
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - L Alcoberro
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - A Garay
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - P Moliner
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - E Calvo
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | | | - J Comin-Colet
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| |
Collapse
|
7
|
Jose-Bazan N, Jimenez-Marrero S, Calero-Molina E, Enjuanes-Grau C, Ruiz-Munoz M, Hidalgo-Quiros E, Ras M, Yun-Viladomat S, Alcoberro L, Ramos-Polo R, Garay A, Garcimartin P, Calvo E, Moliner P, Comin-Colet J. Fragility influences the impact of self-care behavior on patient-reported outcomes further of psychosocial factors of self-perceived health status in patients with heart failure. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Poor self-care behaviour is associated with a higher risk of readmission and mortality in patients with heart failure (HF). Psychosocial factors are key determinants of patient-reported outcomes (PROMs) such as health-realted quality of life (QoL). Little is known about the interplay between self-care and psychosocial factors on PROMs in HF.
Purpose
To describe the interaction of self-care and psycho-social factors on QoL in a real-world cohort of HF patients.
Methods
We conducted an observational, prospective, cohort study of 1120 consecutive patients with chronic. We used the modified European Heart Failure Self-care Behaviour Scale 9-item version (EHFSCBS-9) to measure self-care (inverted and standardised: higher scores indicate better self-care). To assess QoL, we used Minnesota Living with Heart Failure Questionnaire (MLHFQ) (higher scores indicate worse QoL). General linear models (GLM) were constructed to explore the interaction between psychosocial factors and poor self-care (defined as EHFSCBS-9 ≤lower tertile) on adjusted MLHFQ scores. To determine the impact of self-care, multivariate linear regressions models to predict QoL were constructed stratified according to selected psycho-social determinants. All models were adjusted by age, sex and psycho-social determinants of QoL including literacy, cognitive function (Pfeiffer test), dependency (Barthel and Lawton & Brody test), social support (Duke UNC and APGAR Familyfunction), depressive symptoms (15-item Geriatric Depression Scale) and fragility (Barber test scores ≥1).
Results
A total of 484 patients (43%) were women, mean age was 72±11 years, and mean LVEF was 45±17%. Mean MLHFQ scores were 45±24. Mean EHFSCBS-9 scores were 69±28. There was a significant inverse correlation between EHFScBS-9 and MLHFQ scores (r=−0.158; p-value <0.0001). Fragility was present in 883 patients (79%). In adjusted GLM, poor self-care (F=10.2; p-value=0.001) and fragility (F=17.9; p-value <0.001) were independent predictors of higher adjusted scores in the MLHFQ indicating worse QoL. As shown in Figure 1, the interaction between fragility and self-care was significant (F=6.8; p-value = 0.009). Linear regression models (Table 1) stratified according the absence (panel A) or the presence (panel B) of fragility showed that fragility modulated the association between self-care behaviour and QoL. Only in patients without fragility, self-care were independent predictors of QoL. On the other hand, in patients with fragility, self-care behaviour did not longer influence self-perceived health status in patients with HF.
Conclusions
We have shown that self-care behaviour is an independent predictor of PROMs in HF regardless the presence of important psycho-social determinants of QoL only when fragility status is taken into account. Fragility modulates the influence of self-care and QoL, including each one of its dimensions.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- N Jose-Bazan
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - S Jimenez-Marrero
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - E Calero-Molina
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - C Enjuanes-Grau
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - M Ruiz-Munoz
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - E Hidalgo-Quiros
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - M Ras
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - S Yun-Viladomat
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - L Alcoberro
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - R Ramos-Polo
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - A Garay
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | | | - E Calvo
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - P Moliner
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - J Comin-Colet
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| |
Collapse
|
8
|
Jose-Bazan N, Jimenez-Marrero S, Ramos-Polo R, Enjuanes-Grau C, Alcoberro L, Hidalgo-Quiros E, Ras M, Calero-Molina E, Ruiz-Munoz M, Yun-Viladomat S, Garay A, Moliner P, Garcimartin P, Calvo E, Comin-Colet J. DAMOCLES project show that cognitive function is a strong determinant of the influence of self-care behavior on health-related quality of life in patients with heart failure. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Poor self-care is associated with a poorer outcomes in patients with heart failure (HF). Psycho-social factors are determinants of patient-reported outcomes (PROMs) such as health-realted quality of life (QoL). However, little is known about the interplay between self-care and psychosocial factors such as cognitive function on PROMs in patients with HF.
Purpose
Describe the effect of self-care on QoL across cognitive function and explore whether the interaction between self-care and cognitive function may account for this effect.
Methods
1120 patients with chronic HF from DAMOCLES study were analyzed. We used the modified European Heart Failure Self-care Behaviour Scale 9-item version (EHFSCBS-9) to measure self-care (inverted and standardised: higher scores indicate better self-care). To assess QoL, we used Minnesota Living with Heart Failure Questionnaire (MLHFQ) (higher scores indicate worse QoL). Cognitive function was evaluated using Mini-Mental State Examination (MMSE) and Short Portable Mental State Questionnaire (SPMSQ) Tests. Cognitive impairment was defined as abnormal age-and-literacy-adjusted scores. General linear models (GLM) were constructed to explore the interaction between cognitive function and poor self-care (defined as EHFSCBS-9 ≤lower tertile) on adjusted MLHFQ scores. To determine the impact self-care, multivariate linear regressions models to predict QoL were constructed stratified according to cognitive function. All models were adjusted by determinants of HF severity.
Results
Mean age was 72±11 years, 43% were women and mean LVEF was 45±17%. Lower MMSE scores (β=−0,163; p-value <0.001) and >3 errors in the SPMSQ indicating cognitive impairment (β=0.071; p-value = 0.023) were associated with higher scores in the MLHFQ. These associations were confirmed in multivariare linear regression models (β=0.062; p-value = 0.038). In adjusted GLM, poor global self-care (F=4.8; p-value = 0.029) was an independent predictor of higher adjusted scores in the MLHFQ. Interaction term poor self-care by cognitive impairment was significantly associated with MLHFQ scores (F=6.0; p-value=0.014; Figure 1). Multivariate linear regresion models (Table 1) stratified according the absence (panel A) or the presence (panel B) of cognitive impairment showed that cognitive function modulates the association between self-care behaviour and QoL. This effect was only seen in patients without cognitive impairment. In patients with cognitive dysfunction, self-care behaviour did not longer influence self-perceived health status in patients with HF.
Conclusions
Self-care behaviour is an independent predictor of PROMs in HF regardless cognitive disfunction. Cognitive function modulates 1) influence of global self-care and each one of its dimensions on emotional QoL and 2) impact of global self-care and consulting behaviour on global and social QoL.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- N Jose-Bazan
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - S Jimenez-Marrero
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - R Ramos-Polo
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - C Enjuanes-Grau
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - L Alcoberro
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - E Hidalgo-Quiros
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - M Ras
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - E Calero-Molina
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - M Ruiz-Munoz
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - S Yun-Viladomat
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - A Garay
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - P Moliner
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | | | - E Calvo
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - J Comin-Colet
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| |
Collapse
|
9
|
Rivero Santana B, Caro Codon J, Juarez Olmos V, Martinez Monzonis A, Zatarain-Nicolas E, Moliner P, Cadenas Chamorro R, Severo Sanchez A, Valbuena Lopez S, Zamora Aunon P, Gomez Prieto P, Gonzalez Juanatey JR, Lopez-Sendon J, Lopez De Sa E, Lopez-Fernandez T. HFA-ICOS cardiovascular toxicity risk score validation in CARDIOTOX registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Cancer therapy-related cardiovascular toxicity (CTox) is a growing medical problem and baseline cardiovascular (CV) risk assessment is recommended in all patients scheduled to receive potentially cardiotoxic cancer therapy. Based on literature review, the Heart Failure Association (HFA) Cardio-Oncology working group and the International Cardio-Oncology Society (ICOS) proposed a risk score to predict CTox but, it has not been validated.
Purpose
To validate the HFA-ICOS anthracycline risk assessment score in the CARDIOTOX registry cohort (NCT02039622).
Methods
The CARDIOTOX registry is a prospective multicenter study aiming at identifying factors related with CTox and assessing the utility of clinical, biochemical, and echo parameters for the early detection of CV disease during and after cancer therapy. A total of 1324 adult patients were prospectively included from April 2012 to October 2017. Data was collected at baseline, 3 weeks and 3, 6, 12, 18 and 24 months after initiation of treatment. Clinical follow-up was extended until January 2020. All patients receiving anthracycline chemotherapy were stratified according to HFA-ICOS risk score and Kaplan-Meier survival curves were analyzed to estimate the risk of all-cause mortality and anthracycline chemotherapy-related CV complications defined by HFA-ICOS risk score (left ventricular dysfunction (LVD), heart failure (HF) and arrhythmias).
Results
A total of 1066 patients were included in the analysis. Baseline characteristics are summarized in table 1. 571 patients (53.6%) meet low, 333 (31.2%) medium, 152 (14.3%) high and 10 (0.9%) very-high HFA-ICOS CTox risk criteria. 197 patients (18.4%) died of any cause during follow-up. CV death occurred in 4 patients (2%), all caused by HF. Any degree of CTox was identified in 519 (48.7%) patients during the 110 months follow-up (73 (6.8%) developed clinical HF/HF hospitalization, 29 (2.7%) asymptomatic LVEF <50%; 27 (2.5%) clinically relevant arrhythmias and 390 (36.6%) an asymptomatic increase in cardiac biomarkers or a relative decrease in GLS>15%). Figures 1A and 1B showed the cumulative mortality rate and CTox rate during follow-up. CTox and all-cause mortality rates increased significantly according to the estimated baseline HFA-ICOS score.
Conclusions
HFA-ICOS risk score categorizes patients according to their risk of developing anthracycline chemotherapy-related CTox, showing a good ability to predict both all-cause mortality and CTox.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): Instituto de Salud Carlos III (PI13/00559).
Collapse
Affiliation(s)
- B Rivero Santana
- La Paz University Hospital, IdiPaz Research Institute , Madrid , Spain
| | - J Caro Codon
- La Paz University Hospital, IdiPaz Research Institute , Madrid , Spain
| | - V Juarez Olmos
- La Paz University Hospital, IdiPaz Research Institute , Madrid , Spain
| | - A Martinez Monzonis
- University Hospital of Santiago de Compostela, CiberCV , Santiago de Compostela , Spain
| | - E Zatarain-Nicolas
- Gregorio Maranon University General Hospital - Madrid Health Service, Complutense University, CIBER-CV (ISCIII) , Madrid , Spain
| | - P Moliner
- University Hospital Bellvitge , Barcelona , Spain
| | | | - A Severo Sanchez
- La Paz University Hospital, IdiPaz Research Institute , Madrid , Spain
| | - S Valbuena Lopez
- La Paz University Hospital, IdiPaz Research Institute , Madrid , Spain
| | - P Zamora Aunon
- University Hospital La Paz, Oncology Department. IdiPaz Research Institute. CIBER ONC , Madrid , Spain
| | - P Gomez Prieto
- University Hospital La Paz, Hematology Department. IdiPaz Research Institute , Madrid , Spain
| | - J R Gonzalez Juanatey
- University Hospital of Santiago de Compostela, CiberCV , Santiago de Compostela , Spain
| | - J Lopez-Sendon
- University Hospital La Paz, IdiPaz Research Institute. UAM , Madrid , Spain
| | - E Lopez De Sa
- La Paz University Hospital, IdiPaz Research Institute , Madrid , Spain
| | - T Lopez-Fernandez
- La Paz University Hospital, IdiPaz Research Institute , Madrid , Spain
| |
Collapse
|
10
|
Alcoberro L, Jimenez-Marrero S, Cainzos-Achirica M, Monterde D, Enjuanes C, Jose N, Garay A, Moliner P, Yun S, Ramos R, Ras M, Calero E, Hidalgo E, Corbella X, Comin-Colet J. Factors associated to renin-angiotensin-aldosterone system inhibitors discontinuation or down-titration due to hyperkalaemia in patients with chronic cardiovascular conditions. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
The renin-angiotensin-aldosterone system inhibitors (RAASI) are one of the keystones of the medical treatment in chronic cardiovascular disorders and have shown improvements in clinical outcomes in many clinical trials. Hyperkalaemia is a well-defined non-desirable effect of RAASI that occasionally forces to interrupt these medications. That enforced RAASI discontinuation or down-titration due to hyperkalaemia may have adverse prognostic consequences.
Purpose
Describe the demographical, clinical and pharmacological variables associated to a higher risk of RAASI discontinuation or down-titration due to hyperkalaemia among individuals with chronic cardiovascular conditions.
Methods
We used data from more than 375,000 individuals 55 years of age or older, included in the population-based healthcare database of a public Institute of Health between 2015 and 2017. We included participants with at least one relevant condition: chronic heart failure, chronic kidney disease, diabetes mellitus, ischemic heart disease or hypertension. They had to be under RAASI treatment as of January 1st, 2016, and with evidence of at least one episode of hyperkalaemia (serum potassium >5.0 mmol/L) during 2016. Then, were classified in one of the two following profiles: RAASI treatment discontinuation or down-titration versus RAASI treatment unchanged or up-titrated. For the statistical analysis, we used logistic regression to calculate the multivariable-adjusted odds ratios of each study variable, comparing RAASI discontinuation or down-titration group to RAASI treatment unchanged or up-titrated controls (reference group).
Results
In the multivariable-adjusted model, the risk of RAASI treatment discontinuation or down-titration due to hyperkalaemia was significantly associated with the use of RAASI, very high comorbidity index, potassium derangements (both hypokalaemia and hyperkalaemia), prior hospitalizations and prior emergency visits. Among RAASI treatments, the use of Angiotensin receptor blockers (OR 2.518, 95% CI 2.317–2.735) and Angiotensin-converting enzyme inhibitors (OR 2.341, 95% CI 2.149–2.549) were associated with a higher risk of RAASI discontinuation or down-titration due to hyperkalaemia than Aldosterone inhibitors (1.428, 95% CI 1.285–1.584).
Conclusion
These results suggest that vulnerable populations such as those with very high comorbidity index, potassium derangements or prior emergency visits or hospitalizations have a higher risk of RAASI treatment discontinuation or down-titration due to hyperkalaemia.
A more careful and exhaustive management of RAASI should be advised in those patients.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Josep Comin-Colet has received speaker fees from Vifor Pharma.
Collapse
Affiliation(s)
- L Alcoberro
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - S Jimenez-Marrero
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | | | - D Monterde
- Department of Health , Barcelona , Spain
| | - C Enjuanes
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - N Jose
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - A Garay
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - P Moliner
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - S Yun
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - R Ramos
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - M Ras
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - E Calero
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - E Hidalgo
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - X Corbella
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - J Comin-Colet
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| |
Collapse
|
11
|
Jimenez-Marrero S, Cainzos-Achirica M, Monterde D, Enjuanes C, Garay A, Moliner P, Alcoberro L, Yun S, Ras M, Ramos R, Calero E, Hidalgo E, Jose N, Corbella X, Comin-Colet J. Management of renin-angiotensin-aldosterone system inhibitors in patients with chronic cardiovascular conditions and its association with clinical outcomes. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
In chronic cardiovascular diseases, the renin-angiotensin-aldosterone system inhibitors (RAASI) are one of the keystones of the medical treatment and have revealed improvements in clinical outcomes in many clinical trials. In contrast, is well defined as non-desirable effect of RAASI the development of hyperkalemia, which could force to interrupt these treatments. Hyperkalemia has been associated with worse outcomes in observational studies. Though, it is controversial if those negative outcomes in hyperkalemic patients could be because the potassium derangement itself or the circumstance that in these individuals could be enforced to discontinue RAASI medications with prognostic consequences at mid- to long-term.
Purpose
Assess associations between management of RAASI and clinical outcomes among individuals with chronic cardiovascular conditions and hyperkalemia.
Methods
Data from more than 375,000 individuals 55 years of age or older were analyzed, in a population-based healthcare database of a public Institute of Health between 2015 and 2017. We conducted a longitudinal analysis, in which participants with at least one relevant condition were included: chronic heart failure, chronic kidney disease, diabetes mellitus, ischemic heart disease or hypertension. They had to be under RAASI treatment as of January 1st, 2016, and with evidence of at least one episode of hyperkalemia (serum potassium >5.0 mmol/L) during 2016. Then, were classified in one of the two following profiles: RAASI treatment discontinuation or down-titration versus RAASI treatment unchanged or up-titrated. Subsequently, all-cause death and hospitalization has been assessed in the follow-up period as clinical outcomes. For the statistical analysis, we calculated unadjusted incidence rate ratios and Cox Proportional Hazards Regression models to calculate the multivariable-adjusted risk ratios for the clinical endpoints comparing both groups.
Results
There was found an association with mortality and hospitalization for the RAASI treatment interruption/down-titration group when compared unadjusted incidence rate ratios of each clinical endpoints to RAASI treatment unchanged patients (reference group). We presented these results in a Kaplan-Meier survivor curves for endpoint mortality (Figure 1). In the multivariable-adjusted model, the risk of mortality and hospitalization was associated mainly with older age, hypokalemia and down-titration of RAASI treatments, achieving statistical significance (Table 1). The risk ratio for mortality associated with down-titration and with hyperkalemia compared with the reference group was 1.676 (95% CI 1.54–1.82) and 1.161 (95% CI 1.07–1.26) respectively.
Conclusion
These results suggest that the worse outcomes in hyperkalemia individuals could be influenced more for the discontinuation of RAASI prognostic drugs then for the hyperkalemia itself. It is necessary clinical randomized trials to confirm this observational hypothesis.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Josep Comin-Colet has received speaker fees from Vifor Pharma
Collapse
Affiliation(s)
| | | | - D Monterde
- Department of Health , Barcelona , Spain
| | - C Enjuanes
- University Hospital of Bellvitge, Cardiology , Barcelona , Spain
| | - A Garay
- University Hospital of Bellvitge, Cardiology , Barcelona , Spain
| | - P Moliner
- University Hospital of Bellvitge, Cardiology , Barcelona , Spain
| | - L Alcoberro
- University Hospital of Bellvitge, Cardiology , Barcelona , Spain
| | - S Yun
- University Hospital of Bellvitge, Internal Medicine , Barcelona , Spain
| | - M Ras
- University Hospital of Bellvitge, Internal Medicine , Barcelona , Spain
| | - R Ramos
- University Hospital of Bellvitge, Cardiology , Barcelona , Spain
| | - E Calero
- University Hospital of Bellvitge, Cardiology , Barcelona , Spain
| | - E Hidalgo
- University Hospital of Bellvitge, Cardiology , Barcelona , Spain
| | - N Jose
- University Hospital of Bellvitge, Cardiology , Barcelona , Spain
| | - X Corbella
- University Hospital of Bellvitge, Internal Medicine , Barcelona , Spain
| | - J Comin-Colet
- University Hospital of Bellvitge, Cardiology , Barcelona , Spain
| |
Collapse
|
12
|
Comin-Colet J, Capdevila C, Vela E, Cleries M, Fernandez C, Alcober L, Calero-Molina E, Hidalgo E, Jose N, Moliner P, Corbella X, Yun S, Jimenez-Marrero S, Garay A, Enjuanes-Grau C. Effect on mortality and hospitalization of real-world implementation of transitional care heart failure programmes in patients with heart failure: a population-based study in 77,554 patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The efficacy of heart failure programs has been demonstrated in clinical trials but their applicability in the real-world practice setting is more controversial.
Purpose
This study evaluates the efficacy of a comprehensive, transitional-care nurse-based HF programme integrating hospital and primary care resources in a healthcare area covering a population of 209,255 (implementation area).
Methods
We designed a pragmatic, population-based evaluation of the implementation of the program conducting a natural experiment. Study periods were: pre-implementation period (years 2015 and 2016), transition period (year 2017) and consolidation of implementation period (years 2018 and 2019). For the purposes of this study, we included all individuals consecutively admitted to hospital with at least one ICD-9-CM code for HF as the primary diagnosis and discharged alive in Catalonia between January, the 1st, 2015 and December, the 31st of 2019. Efficacy of the implementation of the program was measured at two levels: first, comparing the outcomes of patients exposed to the HF program between periods of implementation taking 2015–2016 as the reference period and, second, comparing outcomes between patients of the implementation area with patients of the remaining areas of the Catalonia at each predefined period.
Results
We included 77,554 patients in the study: 3,396 exposed to the implementation area and 74,158 exposed to the rest of healthcare areas in Catalonia. During the period of the study, 55,886 (72.1%) patients experienced at least one major adverse event. Death occurred in 37,469 (48.3%), clinically related hospitalisation in 41,709 (53.8%) and HF readmission in 29,755 (38.4%).
As shown in Table 1, multivariate Cox proportional hazards models adjusted for age, gender, previous hospitalisation, co-morbidities, socioeconomic status, and time since HF diagnosis showed there was a significant (all p-values <0.001) relative risk reduction of the risk of all-cause death (5%), clinically related hospitalisation (13%) and HF hospitalisation (14%) in the consolidation period (2018–2019) compared to the pre-programme period (2015–2016). Similarly, as shown in Table 1 and Figure 1, while in the pre-programme period (2015–2016) the risk of adverse outcomes was significantly higher in patients exposed to the implementation area compared to the rest of Catalonia, this association was inverted during the consolidation period (2018–2019) where the risk of mortality, clinically-related readmission and HF re-hospitalisation was significantly reduced (all p-values <0.025) by 19%, 11% and 16%, respectively, among patients exposed to the implementation area compared with patients of the remaining areas of Catalonia.
Conclusions
The implementation of multidisciplinary transitional-care nurse-based heart failure programmes integrating hospital and primary care reduce mortality and hospitalisation in vulnerable patients with heart-failure.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - C Capdevila
- University Hospital Bellvitge , Barcelona , Spain
| | - E Vela
- Department of Health , Barcelona , Spain
| | - M Cleries
- Department of Health , Barcelona , Spain
| | - C Fernandez
- Primary Care Research Institute (IDIAP) , Barcelona , Spain
| | - L Alcober
- Primary Care Research Institute (IDIAP) , Barcelona , Spain
| | | | - E Hidalgo
- University Hospital Bellvitge , Barcelona , Spain
| | - N Jose
- University Hospital Bellvitge , Barcelona , Spain
| | - P Moliner
- University Hospital Bellvitge , Barcelona , Spain
| | - X Corbella
- University Hospital Bellvitge , Barcelona , Spain
| | - S Yun
- University Hospital Bellvitge , Barcelona , Spain
| | | | - A Garay
- University Hospital Bellvitge , Barcelona , Spain
| | | |
Collapse
|
13
|
Fort E, Otero S, Moliner P, Bleda C, Prats J, Nadal E, Palmero R, Jimenez L, Piulats JM, Rey M, Fontanals S. Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Oral anticancer therapy is increasingly integrated into the care of patients (pts) with cancer. Recognition and management of pharmacodynamic drug-drug interactions is critical to provide efficacious and safe anticancer treatment.
Purpose
We aimed to gain insight into the real-world prevalence of potentially significant drug-drug interactions of QT-prolonging with oral antineoplastic agents used in an Oncohematological Hospital
Methods
We performed a prospective observational study in an oncohematological hospital between October 2020 and June 2021. Consecutive pts diagnosed with an oncohematological neoplasia and who were evaluated before start treatment with an oral anticancer drug or suport treatment (antibiotics, antivirals) were included. Cancer treatment data were obtained from our prescription software System. Demographic data and concomitant medication were obtained from our electronic medical record software. Micromedex was used to find potencial QT-prolonging interactions between anticancer drugs and chronic medication, and were classified as major or moderate.
Results
Oncohematological treatment was started in 1.217 pts during the study period. A total of 266 potential drug-drug interactions were detected in 171 patients (14.5%). A total of 46 drug-drug interactions of QT-prolonging (17.3%) were detected in 37 pts (21.6%), 22 men and 15 women, with a median age of 66.6 (range 40.9–87.3). Twenty-one (45.7%) and 25 (56.3%) drug interactions of QT-prolonging were classified as major and moderate, respectively, with a median interaction per pts 1.24 (1–3). The 3 most common cancers were: Renal carcinoma in 12 pts (32.4%), non-small cell lung carcinoma in 9 pts (24.7%) and prostate carcinoma in 4 pts (10.8%). The most commonly detected interacting drugs were sunitinib 12 pts (26.1%), osimertinib 10 pts (21.7%), and cabozantinib 5 pts (10.9%) among oncohematological drugs, and citalopram 8 (17.4%), quetiapine 6 (13%) and tramadol 5 (10.8%) among concomitant drugs.
Conclusion
Drug-drug interactions can play a significant role in drugs' cardiac safety in oncohematological pts, specially in renal, lung and prostate cancers, with more than one potential interacting drug or at least one major interaction. Cardiac monitorizacion should be considered when potential drug drug interaction is detected.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- E Fort
- Catalan Institute of Oncology , Barcelona , Spain
| | - S Otero
- Catalan Institute of Oncology , Barcelona , Spain
| | - P Moliner
- Catalan Institute of Oncology , Barcelona , Spain
| | - C Bleda
- Catalan Institute of Oncology , Barcelona , Spain
| | - J Prats
- Catalan Institute of Oncology , Barcelona , Spain
| | - E Nadal
- Catalan Institute of Oncology , Barcelona , Spain
| | - R Palmero
- Catalan Institute of Oncology , Barcelona , Spain
| | - L Jimenez
- Catalan Institute of Oncology , Barcelona , Spain
| | - J M Piulats
- Catalan Institute of Oncology , Barcelona , Spain
| | - M Rey
- Catalan Institute of Oncology , Barcelona , Spain
| | - S Fontanals
- Catalan Institute of Oncology , Barcelona , Spain
| |
Collapse
|
14
|
Comin-Colet J, Capdevila C, Vela E, Cleries M, Fernandez C, Alcober L, Calero-Molina E, Hidalgo E, Jose N, Moliner P, Corbella X, Yun S, Jimenez-Marrero S, Garay A, Enjuanes-Grau C. Effect of socioeconomic status in medical resource use and outcomes in patients with heart failure in integrated care settings: real-world evidence from population-based data of 77,554 patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Low socioeconomic status (SES) has a negative impact in terms of outcomes and medical resource use despite open access to care in universal health-care systems in patients with heart failure (HF). Whether the breach in outcomes determined by SES inequalities can be mitigated by intensive HF management in integrate care programs is not known.
Purpose
To analyse the effect of SES status on health outcomes before and after a pragmatic implementation of an intensive transitional care nurse-based HF management program integrating hospital and primary care and resources for patients with HF at a high risk of events in a health-care area of 209,255 inhabitants.
Methods
For the purposes of this study, we included all individuals consecutively admitted to hospital with at least one ICD-9-CM code for HF as the primary diagnosis and discharged alive in Catalonia between January, the 1st, 2015 and December, the 31st of 2019. We considered 3 distinct periods of implementation of the HF programme: pre-implementation (2015–2016), transition (2017 start of implementation) and consolidation (2018–2019). To evaluate the efficacy of the programme according to SES strata, we compared outcomes between HF patients of the implementation area and HF patients of the remaining healthcare areas of Catalonia across implementation periods and stratified according to levels of SES. SES was defined based on individual annual income.
Results
We included 77,554 patients in the study: 3,396 in the implementation area and 74, 158 in the rest of Catalonia. Distribution of patients according to SES was: 12,018 (15.5%) high or medium SES, 61,967 (79.9%) low SES and 3,535 (4.5%) very low SES. During the period of the study death occurred in 37,469 (48.3%), clinically related hospitalisation in 41,709 (53.8%) and HF readmission in 29,755 (38.4%).
Multivariate Cox proportional hazards models (Table 1) showed that low or very low SES was associated with worse outcomes compared to patients with high or medium SES. Implementation of HF programme significantly improved outcomes in patients with HF (Figure 1, left column). As shown in Figure 1 central and right columns, improvement in clinical outcomes was observed across all SES strata in patients exposed to the HF programme. The size effect for hospitalisation was more prominent among patients with medium of high SES (47% relative change) compared to patients with low or very low SES (32% relative change). Size effect for mortality did not differ between both strata (10% relative improvement in both groups).
Conclusions
The SES is an independent predictor of mortality, clinically related hospitalisation, and HF hospitalisation in vulnerable patients with HF. The implementation of an intensive transitional care nurse-based HF management program improve clinical outcomes across SES strata. However, the size effect in the prevention of hospitalisation is more pronounced among patients with medium or high SES.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - C Capdevila
- University Hospital Bellvitge , Barcelona , Spain
| | - E Vela
- Department of Health , Barcelona , Spain
| | - M Cleries
- Department of Health , Barcelona , Spain
| | - C Fernandez
- Primary Care Research Institute (IDIAP) , Barcelona , Spain
| | - L Alcober
- Primary Care Research Institute (IDIAP) , Barcelona , Spain
| | | | - E Hidalgo
- University Hospital Bellvitge , Barcelona , Spain
| | - N Jose
- University Hospital Bellvitge , Barcelona , Spain
| | - P Moliner
- University Hospital Bellvitge , Barcelona , Spain
| | - X Corbella
- University Hospital Bellvitge , Barcelona , Spain
| | - S Yun
- University Hospital Bellvitge , Barcelona , Spain
| | | | - A Garay
- University Hospital Bellvitge , Barcelona , Spain
| | | |
Collapse
|
15
|
Jose-Bazan N, Jimenez-Marrero S, Calero-Molina E, Moliner P, Hidalgo-Quiros E, Garay A, Ruiz-Munoz M, Ramos-Polo R, Enjuanes-Grau C, Yun-Viladomat S, Calvo E, Alcoberro L, Garcimartin P, Ras M, Comin-Colet J. In patients with chronic heart failure, there have been no gender differences in the impact of self behavior on patient-reported outcomes. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Poor self-care behaviour is associated with a higher risk in heart failure (HF). Gender is a determinant of patient-reported outcomes (PROMs) such as health-realted quality of life (QoL) in HF. Female gender is consistently associated with worse QoL. Whether gender may influence the effect of self-care on PROMS is not known.
Purpose
Describe the effect of self-care on QoL according to gender in a real world cohort of HF patients.
Methods
1120 patients with chronic HF were analysed. We used the modified European Heart Failure Self-care Behaviour Scale 9-item version (EHFSCBS-9) to measure self-care (inverted and standardised: higher scores indicate better self-care). To assess QoL, we used Minnesota Living with Heart Failure Questionnaire (MLHFQ) (higher scores indicate worse QoL). General linear models (GLM) were constructed to explore the interaction between gender and poor self-care (defined as EHFSCBS-9 ≤lower tertile) on adjusted MLHFQ scores. To determine the impact of global self-care and its dimensions, multivariate linear regressions models to predict QoL were constructed stratified according to gender. All models were adjusted by determinants of HF severity.
Results
Mean age was 72±11 years, 43% were women and mean LVEF was 45±17%. There was a significant inverse correlation between EHFScBS-9 and MLHFQ scores (r=−0.158; p-value<0.0001). Unadjusted MLHFQ scores were consistenly higher in women compared to men (49±23 vs. 43±24; p-value<0.001). In adjusted GLM, female gender (F=4.8; p-value=0.028) and poor global self-care (F=12.6; p-value<0.001) were independent predictors of higher adjusted scores in MLHFQ, indicating worse global QoL. As shown in Figure 1, the interaction term gender by poor self-care was not significantly associated with MLHFQ scores in adjusted GLM (F=0.018; p-value=0.893): the gap between women and men in terms of QoL was observed in both self-care strata and the effect of self care on QoL was observed in both genders. Multivariate linear regresion models (Table 1) stratified according to female gender (panel A) or male gender (panel B) showed that higher scores in the EHFScBS-9 were associated with lower scores in the MLHFQ in women and men. This effect (Table 1) was equally seen in both genders for global QoL and was driven by global self-care, consulting behaviour, and in a lesser extent by autonomy-baseda dherence. The physical dimension of QoL was not affected by self-care in either women or men except for consulting behaviour.
Conclusions
Self-care is an independent predictor of health-related QoL in HF, regardless of the level of disease severity. Global self-care, autonomy-based adherence and consulting behaviour were particularly associated with global QoL and emotional and social dimensions of QoL in women and men. In both genders, the effect of self-care on QoL was driven by its effect on emotional and social dimensions. Provider-based adherence did not influence QoL.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- N Jose-Bazan
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - S Jimenez-Marrero
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - E Calero-Molina
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - P Moliner
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - E Hidalgo-Quiros
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - A Garay
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - M Ruiz-Munoz
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - R Ramos-Polo
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - C Enjuanes-Grau
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - S Yun-Viladomat
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - E Calvo
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | - L Alcoberro
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| | | | - M Ras
- Bellvitge University Hospital, Internal Medicine , Hospitalet De Llobregat , Spain
| | - J Comin-Colet
- Bellvitge University Hospital, Cardiology , Hospitalet De Llobregat , Spain
| |
Collapse
|
16
|
Tajes M, Díez-López C, Enjuanes C, Moliner P, Ferreiro JL, Garay A, Jiménez-Marrero S, Yun S, Sosa SG, Alcoberro L, González-Costello J, García-Romero E, Yañez-Bisbe L, Benito B, Comín-Colet J. Neurohormonal activation induces intracellular iron deficiency and mitochondrial dysfunction in cardiac cells. Cell Biosci 2021; 11:89. [PMID: 34001233 PMCID: PMC8130332 DOI: 10.1186/s13578-021-00605-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Accepted: 05/06/2021] [Indexed: 12/17/2022] Open
Abstract
Background Iron deficiency (ID) is common in patients with heart failure (HF) and is associated with poor outcomes, yet its role in the pathophysiology of HF is not well-defined. We sought to determine the consequences of HF neurohormonal activation in iron homeostasis and mitochondrial function in cardiac cells. Methods HF was induced in C57BL/6 mice by using isoproterenol osmotic pumps and embryonic rat heart-derived H9c2 cells were subsequently challenged with Angiotensin II and/or Norepinephrine. The expression of several genes and proteins related to intracellular iron metabolism were assessed by Real time-PCR and immunoblotting, respectively. The intracellular iron levels were also determined. Mitochondrial function was analyzed by studying the mitochondrial membrane potential, the accumulation of radical oxygen species (ROS) and the adenosine triphosphate (ATP) production. Results Hearts from isoproterenol-stimulated mice showed a decreased in both mRNA and protein levels of iron regulatory proteins, transferrin receptor 1, ferroportin 1 and hepcidin compared to control mice. Furthermore, mitoferrin 2 and mitochondrial ferritin were also downregulated in the hearts from HF mice. Similar data regarding these key iron regulatory molecules were found in the H9c2 cells challenged with neurohormonal stimuli. Accordingly, a depletion of intracellular iron levels was found in the stimulated cells compared to non-stimulated cells, as well as in the hearts from the isoproterenol-induced HF mice. Finally, neurohormonal activation impaired mitochondrial function as indicated by the accumulation of ROS, the impaired mitochondrial membrane potential and the decrease in the ATP levels in the cardiac cells. Conclusions HF characteristic neurohormonal activation induced changes in the regulation of key molecules involved in iron homeostasis, reduced intracellular iron levels and impaired mitochondrial function. The current results suggest that iron could be involved in the pathophysiology of HF.
Collapse
Affiliation(s)
- M Tajes
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Díez-López
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Advanced Heart Failure and Heart Transplant Unit, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain
| | - C Enjuanes
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - P Moliner
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - J L Ferreiro
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Garay
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - S Jiménez-Marrero
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - S Yun
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Department of Internal Medicine, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - S G Sosa
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - L Alcoberro
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - J González-Costello
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Advanced Heart Failure and Heart Transplant Unit, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain
| | - E García-Romero
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.,Advanced Heart Failure and Heart Transplant Unit, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
| | - L Yañez-Bisbe
- Vascular Biology and Metabolism Program, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
| | - B Benito
- Vascular Biology and Metabolism Program, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.,Cardiology Department, Hospital Vall d'Hebron Hospital, Barcelona, Spain.,Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - J Comín-Colet
- Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. .,Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. .,Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. .,Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
17
|
Grillo MP, Markova S, Evanchik M, Trellu M, Moliner P, Brun P, Perreard-Dumaine A, Vicat P, Driscoll JP, Carlson TJ. Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy. Xenobiotica 2020; 51:222-238. [PMID: 33078965 DOI: 10.1080/00498254.2020.1839982] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Dilated cardiomyopathy (DCM) is a disease of the myocardium defined by left ventricular enlargement and systolic dysfunction leading to heart failure. Danicamtiv, a new targeted myosin activator designed for the treatment of DCM, was characterised in in vitro and in vivo preclinical studies. Danicamtiv human hepatic clearance was predicted to be 0.5 mL/min/kg from in vitro metabolic stability studies in human hepatocytes. For human, plasma protein binding was moderate with a fraction unbound of 0.16, whole blood-to-plasma partitioning ratio was 0.8, and danicamtiv showed high permeability and no efflux in a Caco-2 cell line. Danicamtiv metabolism pathways in vitro included CYP-mediated amide-cleavage, N-demethylation, as well as isoxazole- and piperidine-ring-opening. Danicamtiv clearance in vivo was low across species with 15.5, 15.3, 1.6, and 5.7 mL/min/kg in mouse, rat, dog, and monkey, respectively. Volume of distribution ranged from 0.24 L/kg in mouse to 1.7 L/kg in rat. Oral bioavailability ranged from 26% in mouse to 108% in dog. Simple allometric scaling prediction of human plasma clearance, volume of distribution, and half-life was 0.64 mL/min/kg, 0.98 L/kg, and 17.7 h, respectively. Danicamtiv preclinical attributes and predicted human pharmacokinetics supported advancement toward clinical development.
Collapse
Affiliation(s)
- Mark P Grillo
- Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA
| | - Svetlana Markova
- Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA.,Jazz Pharmaceuticals Inc, Palo Alto, CA, USA
| | - Marc Evanchik
- Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA.,Drug Metabolism and Pharmacokinetics, Assembly Biosciences Inc R&D Main Facility, South San Francisco, CA, USA
| | - Marc Trellu
- DMPK Research Platform France, Sanofi-Aventis Recherche et Développement, Chilly Mazarin, France
| | | | - Priscilla Brun
- DMPK Research Platform France, Sanofi-Aventis Recherche et Développement, Chilly Mazarin, France
| | - Anne Perreard-Dumaine
- DMPK Research Platform France, Sanofi-Aventis Recherche et Développement, Alfortville, France
| | - Pascale Vicat
- DMPK Research Platform France, Sanofi-Aventis Recherche et Développement, Alfortville, France
| | - James P Driscoll
- Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA
| | - Tim J Carlson
- Drug Metabolism and Pharmacokinetics, MyoKardia Inc, South San Francisco, CA, USA
| |
Collapse
|
18
|
Jimenez S, Cainzos-Achirica M, Monterde D, Garcia-Eroles L, Vela E, Cleries M, Enjuanes C, Yun S, Garay A, Moliner P, Alcoberro L, Calero E, Hidalgo E, Corbella X, Comin-Colet J. 36,269 patients with chronic cardiovascular, metabolic and renal conditions: impact on clinical outcomes, medical resource use and health-related costs of deranged serum potassium levels. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Chronic Heart Failure (CHF) and its risk factors at stage A of the disease are conditions that trends to facilitate potassium (K+) derangements, for pathophysiology mechanisms and medication use than could facilitate both hyper- and hypokalamia. Studies on the associations between potassium derangements and clinical outcomes in these patient populations have yielded mixed findings, and the implications for healthcare expenditure are unknown.
Purpose
The objectives of our analysis was to asses the population-based associations between hyperkalemia, hypokalemia (compared to normokalemia) and all-cause death, urgent hospitalization, emergency department visits, daycare visits, and a yearly healthcare expenditure >85th percentile, in patients with chronic heart failure, chronic kidney disease, diabetes mellitus, hypertension and ischemic heart disease.
Methods
Population-based, longitudinal study including up to 36,269 patients from the Public Healthcare Area with at least one of those conditions. We used three linked administrative, hospital and primary care healthcare databases with exhaustive information on sociodemographics, medical diagnoses, pharmacy dispensing and laboratory data. Participants were identified and followed between 2015 and 2017, had to be ≥55 years old and have at least one serum potassium measurement recorded; and were classified as hyperkalemic, hypokalemic or normokalemic. Four analytic designs were used to evaluate prevalent and incident disease cases as well as prevalent and incident use of renin-angiotensin-aldosterone system inhibitors
Results
The majority of study participants remained normokalemic during the 3 months following study entry (ranging 94%–96%) and hyperkalemia was twice as frequent as hypokalemia. In all analyses, compared to normokalemic patients those with hyperkalemia had a worse crude event-free survival for all endpoints, and the worst survival was observed for hypokalemic patients [see Figure 1: prevalent case analysis; Kaplan-Meier cumulative survivor function curves for all-cause death (upper left), hospitalization (upper right), ED visits (lower left) and daycare visits (lower right)].
In multivariable-adjusted analyses, hyperkalemia was robustly and significantly associated with an increased risk of all-cause death (hazard ratios from Cox regression models ranging 1.31–1.68) and with an increased odds of a yearly healthcare expenditure >85th percentile (odds ratios 1.21–1.29). Associations were even stronger in hypokalemic patients (hazard ratios for all-cause death 1.92–2.60; odds ratios for healthcare expenditure >percentile 85th 1.81–1.85).
Conclusions
Experimental studies are needed to confirm whether prevention of potassium derangements reduces mortality and healthcare expenditure in patients with these chronic conditions. Until then, our findings provide further observational evidence on the potential importance of maintaining normal potassium levels in this setting.
Figure 1
Funding Acknowledgement
Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): The present study was funded by an unrestricted research grant from Vifor Pharma.
Collapse
Affiliation(s)
- S Jimenez
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - M Cainzos-Achirica
- Johns Hopkins University of Baltimore, Baltimore, United States of America
| | | | | | - E Vela
- Department of Health, Barcelona, Spain
| | - M Cleries
- Department of Health, Barcelona, Spain
| | - C Enjuanes
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - S Yun
- University Hospital of Bellvitge, Internal Medicine, Barcelona, Spain
| | - A Garay
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - P Moliner
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - L Alcoberro
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - E Calero
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - E Hidalgo
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - X Corbella
- University Hospital of Bellvitge, Internal Medicine, Barcelona, Spain
| | - J Comin-Colet
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| |
Collapse
|
19
|
Alcoberro L, Vime J, Enjuanes C, Jimenez S, Garay A, Yun S, Moliner P, Guerrero C, Hidalgo E, Calero E, Marin R, Alcober L, Delso C, Comin J. Double check discharge planning to improve the results of a heart failure programme. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Reduction of readmissions in heart failure (HF) patients is a main goal of HF programmes. Establishing a discharge planning for the patient and coordinating it with primary care teams are key aspects for their success.
Purpose
Evaluate whether a double check discharge planning based on adding face-to-face joint weekly sessions with primary care managers to the conventional electronic communication of care plan reduces 6-month readmission and 6-month mortality.
Methods
We evaluated all patients discharged from hospital with HF as primary diagnosis between September 2017 and January 2019. We compared outcomes between patients discharged during Period #1 (single check; September 2017 - April 2018) and those discharged during Period #2 (double check; May 2018 - January 2019).
Primary endpoint was the combined endpoint of all-cause death or all-cause hospitalization 6 months after discharge from the index hospitalization.
Results
The study enrolled 317 patients: 182 in Period #1 and 135 in Period #2.
Mean age was 76±9 years. There was a higher proportion of patients with diabetes and COPD in Period #1, with no differences in other baseline characteristics.
The combined endpoint of all cause-death and all-cause hospitalization at 6 months was significantly reduced in patients in the double check discharge planning group (27% vs. 16%, p 0.021).
Conclusions
In a HF programme, the addition of a double check discharge planning based on having joint weekly sessions with primary care managers on top of the conventional electronic communication of care plan reduces 6-month readmission and 6-month mortality.
Funding Acknowledgement
Type of funding source: Public hospital(s). Main funding source(s): Hospital Universitari de Bellvitge
Collapse
Affiliation(s)
- L Alcoberro
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - J Vime
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - C Enjuanes
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - S Jimenez
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - A Garay
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - S Yun
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - P Moliner
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - C Guerrero
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - E Hidalgo
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - E Calero
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - R Marin
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - L Alcober
- Delta Primary Care Service, ICS, Hospitalet de Llobregat, Spain
| | - C Delso
- Delta Primary Care Service, ICS, Hospitalet de Llobregat, Spain
| | - J Comin
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| |
Collapse
|
20
|
Guerrero G, Alcoberro L, Vime J, Calero E, Hidalgo E, Marin R, Enjuanes C, Garay A, Yun S, Jimenez S, Moliner P, Delso C, Fernandez I, Rosenfeld L, Comin J. Effectiveness of nurse-led hospital-based heart failure programmes in octagenarians and nonagenarians: is age important? Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Efficacy of HF programmes in oldest old (octogenarians and nonagenarians) has not been fully explored.
Methods
We conducted a natural experiment evaluating all patients after hospitalization for heart failure as primary diagnosis between January 2017 and January 2019. We compared outcomes between patients discharged during Period #1, before the implementation of the program with patients discharged during Period #2, after the implementation of the 7-step bundle of interventions. We explored the interaction between age group (<80 vs. ≥80 years old) by the intervention modality (HF programme vs. usual care). Primary end-point was the combined end-point of all-cause death or all-cause hospitalization at 6 months after discharge from the index hospitalization.
Results
The study enroled 440 patients. Mean age of the whole cohort was 75±9 years. In the oldest old subgroup (n=160), mean age was 84±3. No differences were found in baseline characteristics of patients between usual care and HF program. 30-day all-cause readmission was significantly reduced in patients in the HF programme group compared to patients in the usual care group in both age strata. In unadjusted Cox regression analyses in the oldest old group, management of patients in the HF programme was significanty associated with a reduction in the risk of the primary end-point (HR: 0.50; 95% CI [0.29–0.85]; p=0.011).
Conclusions
Management of patients in a nurse-led integrated care-based heart failure programme results in reduction of all-cause death or all-cause hospitalizations in oldest old patients.
Event-free survival cumulative curves.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- G Guerrero
- University Hospital Bellvitge, Barcelona, Spain
| | - L Alcoberro
- University Hospital Bellvitge, Barcelona, Spain
| | - J Vime
- University Hospital Bellvitge, Barcelona, Spain
| | - E Calero
- University Hospital Bellvitge, Barcelona, Spain
| | - E Hidalgo
- University Hospital Bellvitge, Barcelona, Spain
| | - R Marin
- University Hospital Bellvitge, Barcelona, Spain
| | - C Enjuanes
- University Hospital Bellvitge, Barcelona, Spain
| | - A Garay
- University Hospital Bellvitge, Barcelona, Spain
| | - S Yun
- University Hospital Bellvitge, Barcelona, Spain
| | - S Jimenez
- University Hospital Bellvitge, Barcelona, Spain
| | - P Moliner
- University Hospital Bellvitge, Barcelona, Spain
| | - C Delso
- University Hospital Bellvitge, Barcelona, Spain
| | - I Fernandez
- University Hospital Bellvitge, Barcelona, Spain
| | - L Rosenfeld
- University Hospital Bellvitge, Barcelona, Spain
| | - J Comin
- University Hospital Bellvitge, Barcelona, Spain
| |
Collapse
|
21
|
Jimenez S, Cainzos-Achirica M, Monterde D, Garcia-Eroles L, Enjuanes C, Garay A, Yun S, Moliner P, Alcoberro L, Calero E, Hidalgo E, Marin R, Corbella X, Comin-Colet J. Epidemiology of potassium derangements among chronic cardiovascular, metabolic and renal conditions: a population-based analysis data from more than 375,000 individuals. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
In patients with chronic cardiovascular, metabolic and renal disorders, potassium (K)+ homeostasis is often delicate, especially in the presence of renin-angiotensin-aldosterone system inhibition (RAASI) and/or diuretic therapies. In this context, current clinical practical guidelines for the management of these patients recommend close monitoring of renal function and K+ levels, particularly in the presence of drug titration. Nevertheless, very limited epidemiological data on their importance at a population level is available.
Purpose
The objectives of the present analysis are to estimate the prevalence of potassium (K+) derangements in five key chronic cardiovascular, metabolic and renal conditions at the population level, its use of RAASI medication and describe potassium derangements among RAASI users.
Methods
We used data from more than 375,000 individuals 55 years of age or older included in the population-based healthcare database of a public Institute of Health between 2015 and 2017. The conditions of interest were chronic heart failure (CHF), chronic kidney disease (CKD), diabetes mellitus (DM), ischemic heart disease (IHD), and hypertension (HTN). RAASI medications included angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, mineralocorticoid receptor antagonists (MRAs), and rennin inhibitors. Hyperkalemia was defined as K+ levels >5.0 mEq/L and hypokalemia as K+ <3.5 mEq /L
Results
The prevalence of chronic cardiovascular, metabolic and renal conditions was high, particularly of HTN (48.2–48.9%). The prevalence of hyperkalemia was ranging between 10% and 25% depending of the condition, more frequent in CKD and less frequent in HTN patients. In figure, we display the prevalence of hyperkalemia among individuals with each of the relevant chronic conditions, January 1st, 2016 and January 1st, 2017. Use of at least one RAASI medication was very prevalent in HTN patients (75.2–77.3%). Among RAASI users, the frequency of K+ derangements and mainly of hyperkalemia was very noticeable (12% overall), especially in patients with CKD, CHF, elderly individuals, and users of MRAs. Hypokalemia was less frequent (1%).
Conclusion
The high prevalence of K+ derangements and predominantly hyperkalemia among RAASI users highlights the real-world relevance of K+ derangements and the importance of close monitoring and management of K+ levels in routine clinical practice. This is likely to benefit a large number of patients, particularly those at higher risk.
Figure 1. Prevalence of hyperkalemia
Funding Acknowledgement
Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Josep Comin-Colet and Miguel Cainzos-Achirica have participated in other research projects funded by unrestricted grants from Vifor Pharma
Collapse
Affiliation(s)
- S Jimenez
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - M Cainzos-Achirica
- Johns Hopkins University of Baltimore, Baltimore, United States of America
| | | | | | - C Enjuanes
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - A Garay
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - S Yun
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - P Moliner
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - L Alcoberro
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - E Calero
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - E Hidalgo
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - R Marin
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - X Corbella
- University Hospital of Bellvitge, Internal Medicine, Barcelona, Spain
| | - J Comin-Colet
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| |
Collapse
|
22
|
Calero E, Hidalgo E, Rosenfeld L, Fernandez I, Garay A, Alcoberro L, Jimenez S, Yun S, Guerrero C, Moliner P, Delso C, Alcober L, Enjuanes C, Comin-Colet J. Psychosocial and clinical factors associated with poor self-care in patients with chronic heart failure. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Self care is a crucial factor in the education of patients with heart failure (HF) and directly impacts in the progression of the disease.
Beyond heart failure related factors, the role of psychosocial determinants and its interaction with clinical aspects has not been fully explored.
Aims
The aim of the study was to analyze both clinical and psychosocial factors associated with poor self care in patients with chronic HF.
Methods
Self care was evaluated at baseline with the 9 item European HFR Self Care Behaviour Scale (9 item ESCBS).
Scores were standardized and reversed from 0 (worst self care) to 100 (better self care). This study we analysed the associations between poor self care (defined as scores in the lower tertile of the 9 item ESCBS) with demographic, HF-related (clinical) and psychosocial factors in all patients at baseline.
Results
We included 1123 patients: mean age 72±11, 639 (60%) were male, mean LVEF 45±17 and 454 (40%) were in NYHA class III or IV. Mean score of the 9-item ESCBS was 69±28. In the clinical multivariate analyses HF-related factors associated with poor self-care were serum albumins level, ckd level and previous admission due to heart failure. In the psychosocial multivariate analyses poor social support, depressive symptoms and needing a caregiver were independently associated with poor self care. In combined models, only psychosocial factors were independently associated with poor self care whereas no clinical factors remain in the model.
Conclusion
Our study showed that psychosocial conditions are the main factors independently associated with poor self-care in patients with chronic heart failure
Funding Acknowledgement
Type of funding source: Public hospital(s). Main funding source(s): Hospital del Bellvitge
Collapse
Affiliation(s)
- E Calero
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - E Hidalgo
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - L Rosenfeld
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - I Fernandez
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - A Garay
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - L Alcoberro
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - S Jimenez
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - S Yun
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - C Guerrero
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - P Moliner
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - C Delso
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - L Alcober
- Primary Care Centre Just Oliveres, Hospitalet De Llobregat, Spain
| | - C Enjuanes
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - J Comin-Colet
- Hospital Universitari de Bellvitge, Barcelona, Spain
| |
Collapse
|
23
|
Calero E, Hidalgo E, Marin R, Rosenfeld L, Fernandez I, Garay A, Alcoberro L, Jimenez S, Yun S, Guerrero C, Moliner P, Delso C, Alcober L, Enjuanes C, Comin-Colet J. Association between self-care and prognosis in 1123 patients with chronic heart failure. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Self-care is a crucial factor in the education of patients with heart failure (HF) and directly impacts in the progression of the disease. However, little is published about its major clinical implications as admission or mortality in patients with HF.
Aims and methods
The aim of the study was to analyze time to admission due to acute heart failure and mortality associated with poor self-care in patients with chronic HF.
We prospectively recruited consecutive patients with stable chronic HF referred to a nurse-led HF programme. Selfcare was evaluated at baseline with the 9 item European Heart Failure Self-Care Behavior Scale. Scores were standardized and reversed from 0 (worst selfcare) to 100 (better self care). For the purpose of this study we analyzed the associations of worse self-care (defined as scores below the lower tertile of the scale) with demographic, disease-related (clinical) and psychosocial factors in all patients at baseline.
Results
We included 1123 patients, mean age 72±11, 639 (60%) were male, mean LVEF 45±17 and 454 (40,4%) were in NYHA class III or IV. Mean score of the 9-item ESCBE was 69±28. Score below 55 (lower tertile) defined impaired selfcare behaviour.
Those patients with worse self-care had more ischaemic heart disease, more COPD, and they achieved less distance in the 6 minute walking test. Regarding psychosocial items patients in lower tertile of self-care needed a caregiver more frequently, they present more cognitive impairment, depressive symptoms and worse score in terms of health self-perception.
Multivariate Cox Models showed that a score below 55 points in 9-item ESCBE was independently associated with higher readmission due to acute heart failure [HR 1.26 (1.02–1.57), p value=0.034] and with mortality [HR 1.24 CI95% (1.02–1.50), p value=0.028]
Conclusion
Poor self-care measured with the modified 9-item ESCBE was associated with higher risk of admission due to acute decompensation and higher risk of mortality in patients with chronic heart failure.
These results highlight the importance of assessing self-care and provide measures to improve them.
Funding Acknowledgement
Type of funding source: Public hospital(s). Main funding source(s): Hospital Univesitario de Bellvitge
Collapse
Affiliation(s)
- E Calero
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - E Hidalgo
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - R Marin
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - L Rosenfeld
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - I Fernandez
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - A Garay
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - L Alcoberro
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - S Jimenez
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - S Yun
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - C Guerrero
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - P Moliner
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - C Delso
- Institut Catala de la Salut, Barcelona, Spain
| | - L Alcober
- Primary Care Centre Just Oliveres, Hospitalet De Llobregat, Spain
| | - C Enjuanes
- Primary Care Centre Just Oliveres, Hospitalet De Llobregat, Spain
| | - J Comin-Colet
- Primary Care Centre Just Oliveres, Hospitalet De Llobregat, Spain
| |
Collapse
|
24
|
Jimenez S, Cainzos-Achirica M, Monterde D, Garcia-Eroles L, Enjuanes C, Garay A, Yun S, Alcoberro L, Moliner P, Hidalgo E, Calero E, Marin R, Corbella X, Comin-Colet J. A population-based analysis in 375,233 cases of heart failure stages A, B and C. Real world epidemiology of prevalence and temporal trends in South-European populations. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Prevalence of congestive heart failure (CHF) and predisposing conditions has described previously. Most of these studies evaluated centre-European or north-American populations. However, the prevalence and evolutionary changes of Heart Failure stages A, B and C has not been fully elucidated in Mediterranean cohorts.
Purpose
To estimate the prevalence of CHF (HF Stage C) and four additional key chronic cardiovascular, metabolic and renal conditions predisposing to the development of CHF (HF Stages A and B) at a population level in a south-European healthcare area. We analysed the evolutionary changes in the prevalence in these five conditions.
Methods
In a healthcare area of 1,3Millions inhabitants, we extracted health related information of all individuals ≥55 years old. We analysed data of 375,233 individuals included in the population-based healthcare database of a public Institute of Health between 2015 and 2017. The conditions of interest were CHF, chronic kidney disease (CKD), diabetes mellitus (DM), ischemic heart disease (IHD) and hypertension (HTN).
Results
The prevalence of chronic conditions was high, particularly of HTN (48.2–48.9%) and DM individuals (14.6–14.8%). The other conditions were less frequent, with prevalence around 2–4% for IHD, 5–9% for CKD and 2–4% for CHF (Table). However, the less frequent conditions had a striking upward trend with over 1,500 new prevalent cases per year between 2015 and 2017 for CHF (45% relative increase), more than 2,500 new prevalent cases for IHD (67% relative increase) and more than 4,000 new prevalent cases per year for CKD (44% relative increase).
Conclusion
In this south European cohort, there were a high prevalence of HTN and DM as risk factors and a significant trend of increasing prevalence in high cost chronic conditions such as CHF, IHD and CKD.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): The present study was funded by an unrestricted research grant from Vifor Pharma.
Collapse
Affiliation(s)
- S Jimenez
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - M Cainzos-Achirica
- Johns Hopkins University of Baltimore, Baltimore, United States of America
| | | | | | - C Enjuanes
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - A Garay
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - S Yun
- University Hospital of Bellvitge, Internal Medicine, Barcelona, Spain
| | - L Alcoberro
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - P Moliner
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - E Hidalgo
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - E Calero
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - R Marin
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - X Corbella
- University Hospital of Bellvitge, Internal Medicine, Barcelona, Spain
| | - J Comin-Colet
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| |
Collapse
|
25
|
Alcoberro L, Vime J, Enjuanes C, Jimenez S, Garay A, Yun S, Moliner P, Guerrero C, Hidalgo C, Calero E, Marin R, Alcober L, Delso C, Comin J. Long-term effectiveness of a nurse-led 7-step transitional intervention programme in heart failure. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Reduction of 30-day readmission in heart failure (HF) patients is a main goal of health-care systems. Programmes to decrease 30-day readmission have successfully reduced it but have failed to neither maintain benefit afterwards nor decrease mortality. Moreover, in many cases the price of reducing 30-day readmission is a mortality increase.
Purpose
Evaluate whether the impact of a fully nurse-led HF programme directed to reduce 30-day readmission and mortality extends to longer periods of time, including 90 days and 180 days after discharge.
Methods
We evaluated all patients discharged from hospital with HF as primary diagnosis between January 2017 and January 2019. We compared outcomes between patients discharged during Period #1 (pre-programme; Jan 2017 - Aug 2017) and those discharged during Period #2 (HF programme; Sept 2017 - Jan 2019).
Primary endpoint was the combined endpoint of all-cause death or all-cause hospitalization 90 days and 180 days after discharge from the index hospitalization.
Results
The study enrolled 440 patients: 123 in Period #1 and 317 in Period #2.
Mean age was 75±9 years. There was a higher proportion of female patients in Period #2 (38.2% vs 26.8%, p=0.025), with no differences in other baseline characteristics.
The combined endpoint of all cause-death and all-cause hospitalization was significantly reduced in patients in the HF programme group, both at 90 days [OR 0.37 (0.22–0.63), p<0.001] and at 180 days [OR 0.27 (CI 0.17–0.43), p<0.001]. Such a decrease was at expense of a reduction in cardiovascular (CV) hospitalization and HF hospitalization.
There were no differences between groups in mortality [OR 0.96 (0.18–5.00), p=0.293].
Conclusions
A fully nurse-led HF programme reduces the combined endpoint of all-cause death and all-cause hospitalization both at 90 days and 180 days after an index discharge for HF.
Such a decrease is driven by a reduction of CV and HF hospitalization, which are maintained over time. There were no differences between groups in mortality.
Funding Acknowledgement
Type of funding source: Public hospital(s). Main funding source(s): Hospital Universitari de Bellvitge
Collapse
Affiliation(s)
- L Alcoberro
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - J Vime
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - C Enjuanes
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - S Jimenez
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - A Garay
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - S Yun
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - P Moliner
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - C Guerrero
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - C Hidalgo
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - E Calero
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - R Marin
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - L Alcober
- Delta Primary Care Service, ICS, Hospitalet de Llobregat, Spain
| | - C Delso
- Delta Primary Care Service, ICS, Hospitalet de Llobregat, Spain
| | - J Comin
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| |
Collapse
|
26
|
Domingo M, Conangla L, Lupon J, De Antonio M, Moliner P, Santiago-Vacas E, Zamora E, Gonzalez B, Diaz V, Rivas C, Velayos P, Santesmases J, Altimir S, Boldo M, Bayes-Genis A. 4307Lung ultrasound in stable ambulatory chronic heart failure patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The role of lung ultrasound (LUS) in diagnosis and response to diuretic treatment of patients with acute HF has been widely studied, but less is known about its value in chronic HF.
Purpose
To assess the prognostic value of LUS in a cohort of chronic HF stable ambulatory patients and to explore the relationship of LUS findings with clinical data, such as NYHA functional class, left ventricular ejection fraction (LVEF) and NTproBNP.
Methods
Consecutive stable ambulatory patients who attended a scheduled follow-up visit in a HF clinic were included. LUS were performed with a pocket device and examined 4 chest areas per side (two anterior and two lateral). Scans were analysed offline by two investigators blinded to clinical data, who evaluated the number of B-lines of each area. The addition number of B-lines of each area and the quartiles of such addition were used for the analyses. The primary outcome end-point was the composite of all-cause death or hospitalization due to HF at one year. Linear regression and Cox regression analyses were performed.
Results
Five-hundred seventy-seven patients were included between July 2016 and July 2017 (age 69±12 years, 72% men). The main HF aetiology was ischemic heart disease (43%) followed by dilated cardiomyopathy (20%). Median HF duration was 79 months (Q1-Q3 38–144). Mean LVEF was 45%±13 (mean LVEF when admitted at the Unit 34%±13). Most patients were in NYHA functional class II (70%), 13% were in class I and 17% in class III. Median NTproBNP was 722 ng/L (Q1-Q3 262–1760). Mean number of B-lines was 5±6 (Q1, 0; Q2, 1–3; Q3, 4–7; Q4, ≥8). The number of B-lines was associated with age (beta-coefficient 0.11, p<0.001), NYHA functional class (beta-coefficient 1.75, p<0.001), and logNTproBNP (beta-coefficient 1.40, p<0.001). Mean number of B-lines according to NYHA functional class was: class I, 3.5±6; class II, 4.9±6; and class III, 7.1±7. During the one year follow-up 47 patients suffered the primary end-point. In total there were 24 HF related hospitalizations and 26 deaths. In Cox regression analysis, Q4 of B-lines showed a double risk of suffering the primary end-point (HR 2.13 [95% CI 1.18–3.84], p=0.01). However, statistically significance was not maintained for LUS results in the multivariable analysis when age, NYHA functional class and logNTproBNP were included in the model, although a 38% increase in the risk of suffering the primary end-point for Q4 was observed (HR 1.38 [95% CI 0.75–2.54], p=0.31).
Conclusion
In outpatients with stable chronic HF, the number of B-lines detected in LUS was associated with age, NYHA functional class and NTproBNP. Patients having ≥8 B-lines had a significant double risk of HF related hospitalization or all-cause death at one year. However, when strongly powerful prognostic variables such as NYHA class and NTproBNP were included in the model LUS did not retain an independent prognostic role.
Collapse
Affiliation(s)
- M Domingo
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - L Conangla
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - J Lupon
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M De Antonio
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - P Moliner
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | | | - E Zamora
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - B Gonzalez
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - V Diaz
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - C Rivas
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - P Velayos
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - J Santesmases
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - S Altimir
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M Boldo
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - A Bayes-Genis
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| |
Collapse
|
27
|
Martin Garcia A, Mitroi C, Chaparro M, Moliner P, Martinez-Monzonis A, Martin-Garcia AC, Asla C, Castro A, Gual-Capllonch F, Marco I, Sanchez-Pablo C, Antunez Ballesteros M, Lopez Sendon JL, Sanchez PL, Lopez-Fernandez T. P687Is sacubitril/valsartan useful in patients with cancer and heart failure? Data from HF-COH Spanish multicenter registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Current guidelines recommend sacubitril/valsartan (S/V) for patients (p.) with heart failure and reduced left ventricular ejection fraction (LVEF) but there is lack of evidence of its efficacy and safety in p. with cancer and heart failure. Our aim was to analyze the potential benefit of S/V in specific cardio-oncology clinics.
Methods
We performed a retrospective multicenter registry (HF-COH) in six Spanish hospitals with cardio-oncology clinics including all p. treated with S/V. Clinical and echocardiographic data, NYHA functional class, type of neoplasms and anti-tumoral treatment were described. Median follow-up was 7.2 [7.9] months.
Results
Sixty-one p. were included (median age was 64 [21] years old; 64%women, 43% hypertensive, 54% dyslipidemics and 28% diabetics). Most of p. (97%) had cancer therapy related cardiac dysfunction (CTRD) with a median time from anti-cancer therapy to CTRD of 40 [132] months. Breast (46%) and hematological (38%) cancers were the most frequent neoplasms, 31% of p. had metastatic disease and 71% had been treated with anthracyclines. In 5% S/V was initiated at CTRCD diagnosis while in 95% S/V was started to improve clinical status in p. already treated with ACE inhibitors or ARBs. 87% were on beta-blocker therapy and 74% on mineralocorticoid receptor antagonists.Maximal S/V titration dose was achieved in 8.2% of p. (24/26mg: 43%; 49/51mg: 33%) S/V was discontinued in 4 p. (reasons: 2 hypotension; 1: renal failure; 1: pruritus)
Baseline NT-proBNP levels, functional class, and LVEF improved at the end of follow-up in p. who continued with S/V (all p values ≤0.01). No statistical differences were found in creatinine clearance or potassium serum levels. Table
Patient parameters before and after S/V Before S/V After S/V P value LVEF (%) 33 [7] 39.5 [15] <0.001 Creatinine (mg/dl) 0.9 [0.4] 0.9 [0.5] 0.15 Creatinine clearance (ml/min) 73 [30] 75 [37] 0.22 Potassium serum levels (mg/dl) 4.5 [0.5] 4.5 [0.6] 0.42 Systolic arterial pressure (mmHg) 116 [23] 112 [27] 0.025 Diastolic arterial pressure (mmHg) 70 [13] 68 [10] 0.498 NT-proBNP (pg/ml) 1831 [3132] 842 [1919] 0.007 NYHA 2.2±0.6 1.6±0.62 <0.001 Values are median [interquartile range] or mean ± standard derivation; S/V: sacubitril-valsartan; LVEF: left ventricle ejection fraction.
Conclusions
Our experience suggests that S/V is well tolerated and improves functional class and left ventricular function parameters in patients with CTRCD.
Collapse
Affiliation(s)
- A Martin Garcia
- Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain
| | - C Mitroi
- University Hospital Puerta de Hierro Majadahonda, Cardiology, Madrid, Spain
| | - M Chaparro
- Virgen de la Macarena Hospital, Cardiology, Sevilla, Spain
| | - P Moliner
- Germans Trias i Pujol Hospital, Cardiology, Badalona (Barcelona), Spain
| | - A Martinez-Monzonis
- University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain
| | - A C Martin-Garcia
- Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain
| | - C Asla
- University Hospital La Paz, Madrid, Spain
| | - A Castro
- Virgen de la Macarena Hospital, Cardiology, Sevilla, Spain
| | - F Gual-Capllonch
- Germans Trias i Pujol Hospital, Cardiology, Badalona (Barcelona), Spain
| | - I Marco
- University Hospital La Paz, Madrid, Spain
| | - C Sanchez-Pablo
- Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain
| | - M Antunez Ballesteros
- Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain
| | | | - P L Sanchez
- Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain
| | | |
Collapse
|
28
|
Zamora E, Gonzalez B, Rivas C, Diaz V, Velayos P, Lupon J, De Antonio M, Domingo M, Moliner P, Santiago-Vacas E, Cachero M, Joaquim C, Alonso N, Santesmases J, Bayes-Genis A. P2607Quick nutritional assessment and prognosis in outpatients with heart failure with mid-range ejection fraction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Nutritional status is an important prognostic factor in patients with heart failure (HF) beyond body mass index, although its prognostic value in patients with mid-range left ventricular ejection fraction (HFmrEF) is not completely elucidated. In a pilot study we observed that the Mini Nutritional Assessment Short Form (MNA-SF) was the best approach for the screening of nutritional status in HF outpatients over others screening tools.
Purpose
To assess the prognostic role of malnutrition or risk of malnutrition in HFmrEF outpatients after the implementation of the MNA-SF screening tool in a routine way in a multidisciplinary HF.
Methods
The MNA-SF screening tool was administered during the global nurse evaluation of patients. The scoring ranges from 0 to 14, being 0 to7 as malnutrition status, 8 to 11 as at risk of malnutrition and 12 to 14 as normal nutritional status. For the present study those patients with malnutrition and at risk of malnutrition were merged and considered abnormal nutritional status. All-cause death was the primary end-point. Univariate and multivariate (backward conditional stepwise) Cox regression analyses were performed.
Results
Since October 2016 to November 2017, 153 HFmrEF patients were studied (mean age 68.8±11.7 years, 72.5% men, body mass index 28.4±4.4, LVEF 44% ± 3, NYHA class I 5.9%, II 86.3%, and III 7.8%). According to the MNA-SF 25 patients were (16.3%) fulfilled criteria of malnutrition (4) or where at risk of malnutrition (21). During a mean follow-up of 17.4±6.1 months, 23 patients died (15%). In the univariate analysis, nutritional abnormal status was significantly associated with all-cause death (HR 2.93 [1.23–7], p=0.02). In the multivariate analysis which included age, sex, NYHA functional class, body mass index, ischemic aetiology of HF and years of duration of HF, abnormal nutritional status remained significantly associated with all-cause mortality (HR 3.64 [1.39–9.54], p=0.009), together with NYHA functional class (HR 7.93 [2.69–23.4], p<0.001) and years of HF duration (HR 1.10 [1.04–1.16], p=0.001).
Conclusions
Nutritional status assessed with the screening MNA-SF was an independent predictor of all-cause death in ambulatory patients with HFmrEF – beyond BMI – together with NYHA functional class and HF duration.
Collapse
Affiliation(s)
- E Zamora
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - B Gonzalez
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - C Rivas
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - V Diaz
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - P Velayos
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - J Lupon
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M De Antonio
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M Domingo
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - P Moliner
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | | | - M Cachero
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - C Joaquim
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - N Alonso
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - J Santesmases
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - A Bayes-Genis
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| |
Collapse
|
29
|
Moliner P, Lupon J, De Antonio M, Domingo M, Santiago-Vacas E, Zamora E, Santesmases J, Diez-Quevedo C, Troya MI, Boldo M, Altimir S, Alonso N, Gonzalez B, Nunez J, Bayes-Genis A. P4150Causes of death in a heart failure clinic in Spain along 17 years. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Advances in heart failure (HF) treatment have achieved a reduction of death in HF patients in the last two decades. Indeed, not only mortality has been reduced but also the mode of death might have been modified through these years.
Purpose
To assess the causes of death in outpatients attended in a HF Unit since the year 2002 up to the year 2018.
Methods
Causes of death were classified as follows: progression of HF (worsening HF or treatment-resistant HF, in the absence of another cause); sudden death (any unexpected death, witnessed or not, of a previously stable patient with no evidence of worsening HF or any other known cause of death); acute myocardial infarction; stroke; procedural (post-diagnostic or post-therapeutic); other cardiovascular causes (e.g., rupture of an aneurysm, peripheral ischemia, or aortic dissection), and non-cardiovascular. Patients who died of unknown cause were excluded from the analysis. Fatal events were identified from the clinical records of patients with HF, hospital wards, the emergency room, general practitioners, or by contacting the patient's relatives. Furthermore, data were verified from the databases of the Catalan and Spanish Health Systems. Trends on every cause of death were assessed by linear regression.
Results
Since August 2001 to May 2018, 2295 HF patients were admitted to the HF clinic (age 66.4±12.8 years, 71% men, 49% from ischemic aetiology, mean LVEF 35.2% ± 14). During the 17 years of the study, 1201 deaths were recorded. Seventy-eight patients (6.5% of deaths) were excluded due to unknown cause of death. The evolution in the mode of death by years is shown in the figure. Two trends were observed: a decrease in sudden death (p=0.05) and a very significant linear increase in non-cardiovascular causes of death (p<0.001). The decrease of sudden death was mainly driven from changes observed in the first 10 years (p=0.014); thereafter the incidence of sudden death remained stable (p=0.18). Remarkably we did not observe significant changes in HF progression as mode of death (p=0.17).
Conclusions
During the 17 years of the study, a very significant trend towards higher percentage of non-cardiovascular deaths was progressively observed. On the other hand, percentage of sudden death showed a gradual decrease, mainly driven from the changes observed in the first 10 years.
Collapse
Affiliation(s)
- P Moliner
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - J Lupon
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M De Antonio
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M Domingo
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | | | - E Zamora
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - J Santesmases
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - C Diez-Quevedo
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M I Troya
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M Boldo
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - S Altimir
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - N Alonso
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - B Gonzalez
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - J Nunez
- University Hospital Clinic of Valencia, Valencia, Spain
| | - A Bayes-Genis
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| |
Collapse
|
30
|
Zamora E, Lupon J, De Antonio M, Domingo M, Moliner P, Santiago-Vacas E, Santesmases J, Boldo M, Diez-Quevedo C, Troya MI, Rivas C, Gonzalez B, Diaz V, Velayos P, Bayes-Genis A. P6330Obesity paradox in heart failure with mid-range ejection fraction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Obesity is identified as an independent risk factor for developing congestive heart failure (HF). Paradoxically it has been reported that obesity is associated with improved survival in different cohorts of HF patients. Nevertheless, the presence of obesity paradox in HF with mid-range ejection fraction (HFmrEF) is not completely elucidated.
Objective
To analyse the relationship between body mass index (BMI) and mortality in a HFmrEF ambulatory cohort of different aetiologies followed in a HF unit, with especial focus on the role of obesity in prognosis.
Methods
Baseline BMI was analysed as continuous variable and categorized in 4 groups based on 2009 WHO classification: low weight (BMI <20.5 kg/m2), normal weight (BMI 20.5 to <25.5 kg/m2), overweight (BMI 25.5 to <30 kg/m2) and obesity (BMI ≥30 kg/m2). All-cause mortality was the primary end-point of the study. Cox regression analyses adjusted by age, sex and NYHA functional class were performed and survival curves plotted.
Results
Three-hundred thirty patients were included in the study (age 65.9±13.2 years, 68% men). The main aetiology was ischemic heart disease (52%, followed by dilated cardiomyopathy (11%) and hypertensive cardiomyopathy (11%). The majority of patients were in NYHA class II (65%) and III (26%). Mean ejection fraction was 43.2% ± 2.7. During a mean follow-up of 5.3±4.6 years 142 patients (42%) died. BMI showed a protective effect on survival in Cox regression analysis (HR 0.96 [95% CI 0.92–0.99], p=0.01). When categorized groups of BMI were analysed, obese patients showed a trend towards lower mortality than normal weight patients (reference): adjusted HR 0.65 [95% CI 0.40–1.03], p=0.07. Survival curves adjusted by age, sex and NYHA functional class according to BMI category are depicted in the figure. As a significant interaction (p=0.02) was found between BMI and ischemic aetiology of HF, separate analyses were performed for BMI categories for ischemic and non-ischemic patients, with remarkably different results: ischemic aetiology: HR 0.97 [95% CI 0.52–1.79], p=0.91; non-ischemic aetiology HR 0.28 [95% CI 0.13–0.64], p=0.003.
Conclusions
A greater BMI was associated with lower mortality rates in patients with HFmrEF during a mean follow-up of five years. Obesity showed a protective effect in HFmrEF patients, which remarkable in patients from non-ischemic aetiology and was absent in patients from ischemic aetiology.
Collapse
Affiliation(s)
- E Zamora
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - J Lupon
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M De Antonio
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M Domingo
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - P Moliner
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | | | - J Santesmases
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M Boldo
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - C Diez-Quevedo
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - M I Troya
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - C Rivas
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - B Gonzalez
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - V Diaz
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - P Velayos
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | - A Bayes-Genis
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| |
Collapse
|
31
|
Moliner P, Lupon J, Cediel G, De Antonio M, Domingo M, Zamora E, Nunez J, Santiago E, Gonzalez B, Rivas C, Diaz V, Santesmases J, Diez-Quevedo C, Boldo M, Bayes-Genis A. P1815Prediction of sudden death in outpatients with heart failure: a bio-clinical approach. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- P Moliner
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - J Lupon
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - G Cediel
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M De Antonio
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M Domingo
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - E Zamora
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - J Nunez
- University Hospital Clinic of Valencia, Valencia, Spain
| | - E Santiago
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - B Gonzalez
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - C Rivas
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - V Diaz
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - J Santesmases
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - C Diez-Quevedo
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M Boldo
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Bayes-Genis
- Germans Trias i Pujol University Hospital, Badalona, Spain
| |
Collapse
|
32
|
Diaz V, Agostinho J, Gonzalez B, Rivas C, Velayos P, Puertas M, Ros A, Benito N, Morales A, Cachero M, Lupon J, De Antonio M, Moliner P, Domingo M, Bayes-Genis A. 26Perception of symptoms, concerns and global disease experience in patients with heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- V Diaz
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - J Agostinho
- Cardiology Department, Santa Maria Hospital, CHLN, CCUL, Lisbon University, Lisbon, Portugal
| | - B Gonzalez
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - C Rivas
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - P Velayos
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M Puertas
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Ros
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - N Benito
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Morales
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M Cachero
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - J Lupon
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M De Antonio
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - P Moliner
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M Domingo
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Bayes-Genis
- Germans Trias i Pujol University Hospital, Badalona, Spain
| |
Collapse
|
33
|
De Antonio M, Lupon J, Gavidia-Bovadilla G, Lopez-Ayerbe J, Moliner P, Domingo M, Ferrer E, Perera A, Nunez J, Zamora E, Vallejo N, Gual F, Teis A, Junca G, Bayes-Genis A. P5656Heart failure with preserved ejection fraction (HFpEF) infrequently evolves towards a HFpEF-declined phenotype. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M De Antonio
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - J Lupon
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | | | - J Lopez-Ayerbe
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - P Moliner
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M Domingo
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - E Ferrer
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Perera
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - J Nunez
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - E Zamora
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - N Vallejo
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - F Gual
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Teis
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - G Junca
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Bayes-Genis
- Germans Trias i Pujol University Hospital, Badalona, Spain
| |
Collapse
|
34
|
Gonzalez B, Cachero M, Rivas C, Diaz V, Ros A, Benito N, Puertas M, Morales A, Velayos P, Lupon J, De Antonio M, Moliner P, Domingo M, Zamora E, Bayes-Genis A. 411Mini nutritional assessment short form tool for nurse quick screening of nutritional status in an outpatient heart failure unit. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- B Gonzalez
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M Cachero
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - C Rivas
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - V Diaz
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Ros
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - N Benito
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M Puertas
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Morales
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - P Velayos
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - J Lupon
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M De Antonio
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - P Moliner
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - M Domingo
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - E Zamora
- Germans Trias i Pujol University Hospital, Badalona, Spain
| | - A Bayes-Genis
- Germans Trias i Pujol University Hospital, Badalona, Spain
| |
Collapse
|
35
|
|
36
|
De Antonio M, Lupon J, Lopez-Ayerbe J, Moliner P, Domingo M, Ferrer E, Zamora E, Vallejo N, Gual F, Teis A, Junca G, Troya M, Rodriguez M, Gonzalez B, Bayes-Genis A. P443Very long-term monitoring of left ventricular function in patients with HFrEF and HFmrEF. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Pacho C, Domingo M, Nunez R, Lupon J, Revuelta-Lopez E, Barallat J, Moliner P, Gonzalez B, Rodriguez M, Rivas C, Diaz V, Santesmases J, De Antonio M, Tor J, Bayes-Genis A. P2462Prediction of 30-day heart failure readmission and death with early post-discharge ST2 and NT-proBNP. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Gonzalez B, Gastelurrutia P, Lupon J, Rodriguez M, Moliner P, Rivas C, De Antonio M, Domingo M, Diaz V, Zamora E, Armesto T, Puertas M, Cachero M, Morales A, Bayes-Genis A. P2986Frailty and quality of life in heart failure patients with mid-range ejection fraction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p2986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
De Antonio M, Lupon J, Barallat J, Domingo M, Nunez-Villota J, Moliner P, Zamora E, Rivas C, Gonzalez B, Diaz V, Rodriguez M, Santesmases J, Diez-Quevedo C, Pastor C, Bayes-Genis A. P590Prognostic value of a panel of biomarkers in heart failure with mid-range ejection fraction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Lupon J, De Antonio M, Vila J, Subirana I, Galan A, Zamora E, Moliner P, Domingo M, Gonzalez B, Rodriguez M, Rivas C, Barallat J, Santesmases J, Diaz V, Bayes-Genis A. P2455The Barcelona-Bio-HF-calculator upgrade: heart failure hospitalization and all-cause death up to 5 years. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Moliner P, Gastelurrutia P, Lupon J, Yang X, De Antonio M, Domingo M, Altimir S, Gonzalez B, Rodriguez M, Rivas C, Fung E, Zamora E, Santesmases J, Woo J, Bayes-Genis A. P610Frailty, co-morbidities and survival in heart failure patients with mid-range ejection fraction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Moliner P, Lupon J, Barallat J, De Antonio M, Nunez-Villota J, Domingo M, Zamora E, Altimir S, Pastor C, Rodriguez M, Boldo M, Puertas M, Troya M, Diaz V, Bayes-Genis A. P2298Multimarker panel of cardiac biomarkers in patients with heart failure and mid-range ejection fraction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Enache R, Sawada N, Molina Ferragut L, Monney P, Jobbe Duval A, Peluso D, Beladan CC, Diego Bellavia DB, Popa E, Jurcut R, Badea R, Calin A, Beladan CC, Rosca M, Platon P, Coman IM, Popescu BA, Ginghina C, Kawata T, Daimon M, Kimura K, Nakao T, Chiang S, Mahara K, Okubo T, Yatomi Y, Komuro I, Uhl D, Gomez M, Ble M, Mas-Stachurska A, Cladellas M, Enjuanes C, Moliner P, Marti J, Comin J, Ehret G, Crisinel V, Reverdin S, Conti L, Mach F, Jeanrenaud X, Bochud M, Mueller H, Thebault O, Poilane M, Piriou N, Jaafar P, Warin-Fresse K, Serfaty JM, Cueff C, Le Tourneau T, Kovacs A, Surkova E, Muraru D, Perazzolo Marra M, Iliceto S, Badano LP, Predescu L, Platon P, Mateescu AD, Enache R, Calin A, Rosca M, Egher L, Inta O, Jurcut R, Ginghina C, Popescu BA, Attilio Iacovoni AI, Sonia Dell'oglio SD, Giuseppe Romano GR, Michele Senni MS, Chiara Mina' CM, Gabriele Di Gesaro GD, Michele Pilato MP, Fletcher Miller FAM, Cesare Scardulla CS, Francesco Clemenza FC, Joseph Maalouf JM, Michael Dandel MD. Moderated Posters: Imaging of the right heart - What is new?P814Prognostic value of parameters of pulmonary artery stiffness in patients with pulmonary hypertension receiving specific vasodilator therapyP815Reconsidering of inferior vena cava parameters for estimating right atrial pressure: a comparative simultaneous ultrasound-catheterization studyP816Pulmonary hypertension is the main factor echocardiography to predicting mortality in medium and long term in a cohort of patients with heart failureP817Normal values for 3D-right atrial volumes : results from the SKIPOGH-II population studyP818Assessment of right ventricular function by free wall longitudinal strain in organic mitral regurgitationP819Importance of radial dysfunction to determine the impairment of right ventricular ejection fraction in patients with pulmonary hypertensionP820Influence of tricuspid regurgitation severity on non-invasive assessment of right heart hemodynamics: a simultaneous echocardiography-catheterization studyP821Right ventricular failure following ventricular assist device implant: systematic review and meta-analysis of clinical and echocardiographic predictors. Eur Heart J Cardiovasc Imaging 2016. [DOI: 10.1093/ehjci/jew255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
44
|
Vivares A, Salle-Lefort S, Arabeyre-Fabre C, Ngo R, Penarier G, Bremond M, Moliner P, Gallas JF, Fabre G, Klieber S. Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device. Xenobiotica 2014; 45:29-44. [PMID: 25068923 DOI: 10.3109/00498254.2014.944612] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
1. The quantitative prediction of the pharmacokinetic parameters of a drug from data obtained using human in vitro systems remains a significant challenge i.e. prediction of metabolic clearance in humans and estimation of the relative contribution of enzymes involved in the clearance. This has become particularly problematic for low turnover compounds. 2. Having human hepatocytes with stable cellular function over several days that adequately mimic the complexity of the physiological environment would be a major advance. Thus, we evaluated human hepatocytes, maintained in culture during 7 days in the microfluidic LiverChip™ system, in terms of morphological appearance, relative mRNA expression of phase I and II enzymes and transporters as a function of time, and metabolic capacity using probe substrates. 3. The results showed that mRNA levels of the major genes for enzymes involved in drug metabolism were well-maintained over a 7-day period of culture. Furthermore, after 4 days of culture, in the Liverchip™ device, human hepatocytes exhibited higher or similar CYPs activities compared to 1 day of culture in 2D-static conditions. 4. The functional data were supported by light/electron microscopies and immunohistochemistry showing viable tissue structure and well-differentiated human hepatocytes: presence of cell junctions, glycogen storage, and bile canaliculi.
Collapse
Affiliation(s)
- Aurelie Vivares
- Drug Disposition Domain, Disposition, Safety and Animal Research Scientific Core Plateform, SANOFI R&D , Montpellier , France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Klieber S, Arabeyre-Fabre C, Moliner P, Marti E, Mandray M, Ngo R, Ollier C, Brun P, Fabre G. Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug. Pharmacol Res Perspect 2014; 2:e00044. [PMID: 25505590 PMCID: PMC4186413 DOI: 10.1002/prp2.44] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Revised: 02/18/2014] [Accepted: 03/04/2014] [Indexed: 11/10/2022] Open
Abstract
The in vitro metabolism of dronedarone and its major metabolites has been studied in human liver microsomes and cryopreserved hepatocytes in primary culture through the use of specific or total cytochrome P450 (CYP) and monoamine oxidase (MAO) inhibitors. The identification of the main metabolites and enzymes participating in their metabolism was also elucidated by using rhCYP, rhMAO, flavin monooxygenases (rhFMO) and UDP-glucuronosyltransferases (rhUGT) and liquid chromatography/tandem mass spectrometry (LC/MS-MS) analysis. Dronedarone was extensively metabolized in human hepatocytes with a metabolic clearance being almost completely inhibited (98 ± 2%) by 1-aminobenzotriazole. Ketoconazole also inhibited dronedarone metabolism by 89 ± 7%, demonstrating the crucial role of CYP3A in its metabolism. CYP3A isoforms mostly contributed to N-debutylation while hydroxylation on the butyl-benzofuran moiety was catalyzed by CYP2D6. However, hydroxylation on the dibutylamine moiety did not appear to be CYP-dependent. N-debutyl-dronedarone was less rapidly metabolized than dronedarone, the major metabolic pathway being catalyzed by MAO-A to form propanoic acid-dronedarone and phenol-dronedarone. Propanoic acid-dronedarone was metabolized at a similar rate to that of N-debutyl-dronedarone and was predominantly hydroxylated by CYP2C8 and CYP1A1. Phenol-dronedarone was extensively glucuronidated while C-dealkyl-dronedarone was metabolized at a slow rate. The evaluation of the systemic clearance of each metabolic process together with the identification of both the major metabolites and predominant enzyme systems and isoforms involved in the formation and subsequent metabolism of these metabolites has enhanced the overall understanding of metabolism of dronedarone in humans.
Collapse
Affiliation(s)
- Sylvie Klieber
- SANOFI-AVENTIS Recherche & Development Disposition, Safety and Animal Research Scientific Core Platform, Drug Disposition Domain 371 Rue du Professeur Joseph Blayac, 34184 Montpellier, Cedex 4, France
| | - Catherine Arabeyre-Fabre
- SANOFI-AVENTIS Recherche & Development Disposition, Safety and Animal Research Scientific Core Platform, Drug Disposition Domain 371 Rue du Professeur Joseph Blayac, 34184 Montpellier, Cedex 4, France
| | - Patricia Moliner
- SANOFI-AVENTIS Recherche & Development Disposition, Safety and Animal Research Scientific Core Platform, Drug Disposition Domain 371 Rue du Professeur Joseph Blayac, 34184 Montpellier, Cedex 4, France
| | - Eric Marti
- SANOFI-AVENTIS Recherche & Development Disposition, Safety and Animal Research Scientific Core Platform, Drug Disposition Domain 371 Rue du Professeur Joseph Blayac, 34184 Montpellier, Cedex 4, France
| | - Martine Mandray
- SANOFI-AVENTIS Recherche & Development Disposition, Safety and Animal Research Scientific Core Platform, Drug Disposition Domain 371 Rue du Professeur Joseph Blayac, 34184 Montpellier, Cedex 4, France
| | - Robert Ngo
- SANOFI-AVENTIS Recherche & Development Disposition, Safety and Animal Research Scientific Core Platform, Drug Disposition Domain 371 Rue du Professeur Joseph Blayac, 34184 Montpellier, Cedex 4, France
| | - Céline Ollier
- SANOFI-AVENTIS Recherche & Development Disposition, Safety and Animal Research Scientific Core Platform, Drug Disposition Domain 371 Rue du Professeur Joseph Blayac, 34184 Montpellier, Cedex 4, France
| | - Priscilla Brun
- SANOFI-AVENTIS Recherche & Development Disposition, Safety and Animal Research Scientific Core Platform, Drug Disposition Domain 371 Rue du Professeur Joseph Blayac, 34184 Montpellier, Cedex 4, France
| | - Gérard Fabre
- SANOFI-AVENTIS Recherche & Development Disposition, Safety and Animal Research Scientific Core Platform, Drug Disposition Domain 371 Rue du Professeur Joseph Blayac, 34184 Montpellier, Cedex 4, France
| |
Collapse
|
46
|
Di Marco A, Ariza A, Moliner P, Marcano A, Sanchez Salado J, Lorente V, Teruel L, Gomez-Hospital JA, Cequier A. Clinical impact of a chronic total oclusion in a non-infarct-related coronary artery in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Becotte A, Moliner P, Devroede G, Knecht H. Succesful management of life-threatening hemorrhage in a patient with osteogenesis imperfecta by low-dose activated recombinant factor VII. Can J Anaesth 2008. [DOI: 10.1007/bf03016404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
48
|
Barbery J, Louche C, Moliner P. Théorie du noyau central et transformation des cultures organisationnelles à l'occasion d'une fusion. Psychologie du Travail et des Organisations 2006. [DOI: 10.1016/j.pto.2006.06.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
49
|
Tudiver F, Brown JB, Medved W, Herbert C, Ritvo P, Guibert R, Haggerty J, Goel V, Smith P, O'Beirne M, Katz A, Moliner P, Ciampi A, Williams JI. Making decisions about cancer screening when the guidelines are unclear or conflicting. J Fam Pract 2001; 50:682-687. [PMID: 11509162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
OBJECTIVE Our purpose was to determine the factors involved in the cancer screening decisions of family physicians in situations where the clinical practice guidelines are unclear or conflicting as opposed to when they are clear and uncontroversial. STUDY DESIGN We analyzed discussions with focus groups using a constant comparative approach. POPULATION A total of 73 family physicians in active practice participated in 10 focus groups (1 urban group and 1 rural group in each of 5 Canadian provinces). OUTCOME MEASURES Our main outcome measures were participants' perceptions regarding cancer screening when the guidelines were unclear or conflicting. RESULTS We propose a model of the determinants of cancer screening decision making with regard to unclear and conflicting guidelines. This model is rooted in the physician-patient relationship, and is an interactive process influenced by patient factors (anxiety, expectations, and family history) and physician factors (perception of guidelines, clinical practice experience, influence of colleagues, distinction between the screening styles of specialists and family physicians, and the amount of time and financial costs involved in performing the maneuver). CONCLUSIONS Our model is unique, because it is embedded in the physician-patient relationship. Ultimately, a modified model could be used to design interventions to assist with the implementation of preventive services guidelines.
Collapse
Affiliation(s)
- F Tudiver
- State University of New York Upstate Medical University, Suite 200, 475 Irving Ave, Syracuse, NY 13210, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|